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Abstract 
Small molecule modulators of SH2-containing inositol 5’-phosphatase (SHIP) have 
recently become a hotly pursued area in medicinal chemistry. Pharmaceutical targeting of SHIP 
with small molecules has been identified as a new method to directly influence the 
phosphoinositide 3-kinase (PI3K) cell signaling pathway. Modulation of this pathway may be 
utilized in the development of interesting new therapeutics. A better understanding of the role that 
SHIP phosphatase activity plays in a number of disease states ranging from cancer to autoimmune 
disease to obesity may be ascertained by use of small molecule inhibitors. These investigations 
involved the synthesis of aminosteroid inhibitors and a variety of aminosteroid analogs to allow 
for further evaluation of structure-activity relationships in these systems for both potency and 
selectivity against both paralogs of SHIP,  SHIP1 (primarily expressed in hematopoietic cells) and 
SHIP2 (expressed across all cell types).  
SHIP1 has also been recognized to be an allosterically activated enzyme, with several small 
molecule agonists having been reported in the literature. These studies have culminated in the 
identification of AQX-1125, which is currently undergoing phase III clinical evaluation for 
interstitial cystitis / bladder pain syndrome. To facilitate our own studies on SHIP1 signaling, a 
new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This route allows for 
more rapid access to AQX-1125 from dehydroepiandrosterone than the published synthetic 
pathway, saving time and resources. Key features of the new route include utilizing an allylic 
oxidation, ozonolysis, and lactonization for a more selective and controlled synthesis. In addition, 
this work has led to the synthesis of several new AQX-1125 analogs, providing information on 
structure activity relationships in this structural class of SHIP1 agonists. 
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Chapter 1 - Potential Therapeutics through SHIP Modulation 
 
1 
1.1 The Phosphoinositide 3-Kinase Cell Signaling Pathway 
Eukaryotic cell development, longevity, and behavior are influenced by the transfer of 
stimuli from the extracellular environment, through the plasma membrane, to the cell nucleus. 
Many of these responses result from signaling cascades initiated by the activation of receptors 
which span the cell membrane. Once initiated the signal is amplified and passed through a complex 
system of protein phosphatases and protein kinases until the reaching the nucleus, where the 
molecular events trigger an appropriate response. Such responses can include rearrangement of the 
cytoskeleton, stimulation of an enzyme, or activation of a gene to drive protein synthesis. These 
actions influence macroscopic processes like cell division, survival, differentiation, or apoptosis.1,2 
Phosphatidylinositols intercalated in the cell membrane play a critical role in this intricate 
signaling network, acting as second messengers to the initial response. These phosphoinositols are 
decorated with lipids that intercalate into the plasma membrane, with the phosphoinositol being 
present on the inside of the plasma membrane. The phosphorylation patterns observed on the 
inositol rings are key to signals being passed on to the nucleus, as these are recognized by other 
protein kinases which pass the signal further on in the pathway.1,3,4 Changes to these 
phosphorylation patterns on these phosphatidylinositols often alter the cell’s course of action and 
may allow for a potential therapeutic intervention in cases where aberrant signaling is injurious.  
The phosphoinositide 3-kinase (PI3K) cell signaling pathway is one of the most heavily 
investigated cell signaling pathways, playing a key role in many cell functions.5 This activity is 
partially attributed to the essential kinase PI3K, which once activated by a receptor tyrosine kinase 
(RTK), phosphorylates the 3’ position of the inositol phospholipid phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2) to generate a higher concentration of phosphatidylinositol-3,4,5-
triphosphate (PI(3,4,5)P3) in the cell (Figure 1.1).5-7 The phosphorylation at 3’ position is believed 
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to amplify the cell signaling cascade primarily through its recruitment and activation of pleckstrin 
homology (PH) containing signaling proteins to the membrane, such as the serine-threonine kinase 
protein kinase B (AKT).5 
 
Figure 1.1: Intrinsic Activation of Cellular Signaling Induced by SHIP 
 
Once activated, AKT drives the continued phosphorylation and activation of other 
intracellular kinases until the signal is received by the cell nucleus prompting events such as 
migration, proliferation, differentiation, and apoptosis (Figure 1.2). To tightly regulate the 
concentration of the PI3K product PI(3,4,5)P3 present in the cell, the key inositol phosphatases 
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(SHIP) are utilized.5,8,9 PI3K’s transduction of information can be negated through the reversal of 
the 3’ phosphorylation by PTEN generating the initial PI(4,5)P2.  
However, PI3K’s effect can also be modified by the hydrolysis of PI(3,4,5)P3 to 
phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) through the 5'-inositol phosphatase SHIP.8 
Reducing the amount of PI(3,4,5)P3 in the system should lead to a decrease in AKT activation as 
SHIP activity increases. The system is more complex, however, as the product of SHIP, PI(3,4)P2, 
has an increased affinity for the AKT PH domain and also activates AKT, with both PI(3,4,5)P3 
and PI(3,4)P2 being required for full activation of AKT.10 Therefore the activity of SHIP can also 
increase AKT activation in some instances. This complication demonstrates that SHIP plays a 
major role in the PI3K pathway due to its ability to both negate and promote cellular signaling. 
 
Figure 1.2: PI3K Signaling Pathway 
 
 Regulation of this delicate balance between PI(3,4,5)P3 and PI(3,4)P2 has been found to 
influence the cellular physiology of blood and bone marrow (hematopoietic) cells,11-13 endothelial 
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pathway may allow for the development of interesting therapeutic treatments for cancer,5,16,17 
autoimmune diseases,2 cardiovascular disease,2 obesity,18,19 and Crohn’s disease.20 Two major 
paralogs of SHIP have been found: SHIP1 (which is utilized primarily hematopoietic cells)21 and 
SHIP2, which is expressed ubiquitously.5 The two enzymes are very homologous, having an ~50% 
identical amino acid sequence in their structure. Interest in SHIP modulation as a potential 
therapeutic strategy has led to the discovery of selective SHIP1 inhibitors, selective SHIP2 
inhibitors, pan-SHIP1/2 inhibitors, as well as SHIP1 agonists. 
 
1.2 Targeting SHIP Modulation for Potential Therapeutics of Human Diseases 
 Positive and negative modulation of SHIP plays a critical role in cell physiology acting as 
a regulator to control cell concentrations of PI(3,4,5)P3 and PI(3,4)P2 present on the cell membrane, 
and therefore influencing downstream signaling. Perturbing this system alters the cells function as 
both of PI(3,4,5)P3 and PI(3,4)P2 are necessary to fully activate the signaling cascade through AKT 
(Figure 1.1). SHIP, PTEN and PI3K are the first soluble signaling proteins that take part in the 
PI3K signaling cascade, which avoids issues of working with membrane proteins as their 
expression, folding and isolation are not hampered by the need for a lipid bilayer. While SHIP is 
one of ten mammalian proteins with an inositol 5-phosphatase domain, it is the only one involved 
in cell signaling pathways.22,23 Inhibition of SHIP using an antagonist would allow for an increase 
in PI(3,4,5)P3 concentrations and a decrease in PI(3,4)P2, while upregulation of SHIP activity by 
agonist would decrease the concentration of PI(3,4,5)P3 and increase PI(3,4)P2. The ability to 
control the balance of these secondary messengers has been shown to be a promising lead to the 
development of potential therapeutics in a number of areas. 
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1.3 SHIP Modulation in Cancer 
Overstimulation of the PI3K-Akt-mTOR signaling pathway has often been implicated in 
facilitating both cell division and survival of cancerous cells, allowing a malignant state to be 
achieved through an overabundance of either PI(3,4,5)P3 or PI(3,4)P2 or both. Targeting SHIP1 in 
hematopoietic cells with the use of small-molecule inhibitors or agonists has been shown to kill 
human blood cancer cells, specifically in leukemia and multiple myeloma cell lines.24,25 The 
targeting of SHIP1 is supported by the lack of activity against cell lines which only express SHIP2 
and do not use SHIP1. For example, the leukemia cell line K562 (that express both PTEN and 
SHIP2, but lack expression of SHIP1) is unaffected by treatment with a selective SHIP1 
inhibitor.24 While SHIP1 inhibitors may be useful for the treatment of blood cancers, they will be 
limited to cancers which utilize SHIP1. Other types of cancer may also be treated with SHIP2 
inhibitors. For example, breast cancer cells solely express the SHIP2 paralog and not SHIP1. Over 
activation of SHIP2 has been shown to lead to increased cell proliferation through EGF-induced 
signaling.5,26-29 The over proliferation of breast cancer line MDA-MB-231 was greatly reduced 
and incurred apoptosis through SHIP2 inhibition28 showing the potential for SHIP2 specific 
therapeutic targets. SHIP2 was also shown to be implicated in the pathogenesis of some types of 
colorectal cancer,30 and treatment with a SHIP2 inhibitor was found to be useful in controlling cell 
growth in these cell lines. In some cases cancer cells may show resistance to selective SHIP1 or 
selective SHIP2 inhibitors by overexpressing the other SHIP paralog.31 In these cases the use of 
pan-SHIP1/2 inhibitors may be employed, as these compounds should limit the development of 
resistance through the paralog compensation mechanism.  
Another potential use for SHIP1 inhibitors in cancer treatment is to prime the immune 
system so that it is more sensitive to cancer immunotherapeutics. SHIP1 is expressed primarily in 
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hematopoietic cells, (mostly blood and bone marrow cells) which make up much of the human 
immune system. SHIP1 limits signaling from receptors that activate natural killer (NK) cells and 
T cells, therefore SHIP1 inhibitors usually are thought of as immunosuppressants. SHIP1 
knockouts unexpectedly showed that the effector functions of SHIP1-deficient NK and T cells are 
compromised in vivo. Implicating that the immunosuppressant effects of SHIP1 inactivation is due 
to chronic activation of immune cells which renders them less responsive to activating signals. 
This effect is thought to be a host mechanism to avoid autoimmunity. Therefore reversible and 
pulsatile inhibition of SHIP1 with a small molecule inhibitor may increase the antitumor response 
of SHIP1 dependent immune cells. Recent experiments have shown that pulsatile inhibition of 
SHIP1 in myeloid cells can amplify the immune response by increasing the proinflammatory 
cytokine production.32 Transient SHIP1 inhibition before challenge with cancer cells in mouse 
models of lymphoma and colon cancer improved the median and long-term tumor-free survival 
rates. These findings suggest that a pulsatile inhibition of SHIP1 prior to use of an 
immunotherapeutic might be more effective than the immunotherapeutic alone in some patients. 
Recently a similar dosing regimen was found to prevent bacterial infection in mice and human 
cells, likely through a similar mechanism of immune stimulation.33 
 
1.4 SHIP Modulation in Diabetes and Obesity 
SHIP2 has been shown to be an important negative regulator of the insulin-signaling 
pathway, and therefore its inhibition can lead to increased insulin sensitivity.5,18,34 As diabetics 
often begin to develop resistance to insulin later in life, the ability to increase sensitivity to the 
protein could be useful as an adjuvant for people with diabetes. The specific role of SHIP2 in 
insulin signaling has been a controversial topic. Some studies have reported that SHIP2 knockout 
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mice have a reduced body weight despite increased food intake.35 Placing these SHIP2 knockout 
mice on a high-fat diet showed that they were highly resistant to weight gain over a 12-week 
period. Over this time period the mice exhibited no increase in serum lipids and did not develop 
hyperglycemia or hyperinsulinemia. These results are attributed to enhanced insulin-stimulated 
AKT and p70S6K activation in the liver and skeletal glucose when compared to normal mice. 
Other SHIP2 knockout mice did not show this phenotype,36 however this work did spur the design 
of new SHIP2 inhibitors as potential treatments for diabetes. Treatment of diabetic db/db mice 
with a selective SHIP2 inhibitor was found to lead to lowered the plasma glucose levels and 
improved glucose tolerance.37 These in vivo effects were based in part on the activation of 
intracellular insulin signaling pathways in the liver, which were consistent with the inhibition of 
SHIP2. 
Additional studies with a pan-SHIP1/2 inhibitor showed that these small molecules may 
also be an effective diabetes therapeutic regimen. In vivo studies showed that mice had a 
significant decrease in body weight and body fat, while maintaining a high fat diet, when 
administered the pan-SHIP1/2 inhibitor K118 compared to vehicle mice.38 Treatment with the pan-
SHIP1/2 inhibitor also maintained healthy blood sugar levels and improved insulin sensitivity. The 
use of a pan SHIP1/2 inhibitor may be superior to the use of a selective inhibitor as the increase in 
glucose sensitivity seen with SHIP2 can act synergistically with the SHIP1 inhibition leading to 
immunocalming in of adipose tissue stress associated with the consumption of a high caloric diet. 
As a key component in the insulin-signaling pathway, development of SHIP1/SHIP2 pan-
inhibitors may be a potential therapeutic target for treatment of diabetes and obesity.  
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1.5 SHIP Modulation in Inflammatory Diseases 
 Continued investigation of the role of SHIP in the PI3K signaling pathway has established 
its ability to be a negative regulator in the cells inflammatory induced response as a controlling 
factor in cytokine secretion.5,39 SHIP1 knockout mice showed inflammation through a myeloid 
cell response as the SHIP1 induced signal to AKT was removed.40 An inflammatory disease 
phenotype was also observed in knockout mice with similarities to human Crohn’s disease.20  
 The possibility of a SHIP1 agonist to upregulate the SHIP1 activation of AKT signaling 
could be a potential therapeutic for inflammatory diseases such as IBD and Crohn's disease. While 
the use of agonists is less precedented than antagonists in the realm of small molecule 
pharmaceuticals, SHIP1 has been shown to be an allosterically modulated enzyme. The product of 
the enzymatic reaction, PI(3,4)P2, binds to SHIP1 at the C2-domain of the enzyme, increasing the 
rate of phosphate hydrolysis in a feed-forward manner.41 SHIP1 agonists have therefore been 
explored as alternatives to PI3K inhibitors, as both mechanisms are effective in lowering 
PI(3,4,5)P3 concentration. 
 
1.6 SHIP Modulation in Alzheimer’s Disease 
 Interestingly, SHIP2 expression has recently been linked to cognitive decline and 
neurodegenerative diseases. Inhibition of SHIP2 was shown to reduce tau hyperphosphorylation 
induced by amyloid ß in Alzheimer’s disease mouse models and rescued memory impairment.42 
With the potential for an Alzheimer’s disease treatment by targeting SHIP2, interest in SHIP2 
inhibitors that cross the blood-brain barrier have been investigated. Lim et. al. identified an active 
SHIP2 inhibitor with an IC50 of 2 µM based on the parent small molecule crizotinib. This inhibitor 
was found through a high-throughput screen and was shown to cross the blood brain barrier. This 
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inhibitor was shown to be effective in HT22 neuronal cells, reducing SHIP2 activation and 
PI(3,4)P2 production.42 Also, suppression of GSK3ß activation, a key signaling event for tau 
hyperphosphorylation, was also observed in the SHIP2 inhibition in HT22 cells.42 Further 
investigations into the development of potent SHIP2 selective inhibitors targeting the brain could 
play a key role in potential Alzheimer’s disease treatments. 
 SHIP1 may also play a role in the development of Alzheimer's disease. Recently a number 
of single nucleotide polymorphisms in the INPP5D (SHIP1) gene have been linked with an 
increase in risk of Alzheimer’s disease.43,44 This suggests that a reduction in SHIP1 activity (as 
could be envisioned with a small molecule inhibitor) could be a viable therapeutic strategy worth 
pursuing to treat Alzheimer's disease.45 This is supported by the role SHIP1 plays in cell signaling 
in myeloid cells, which include microglial cells in the brain. SHIP1 limits signaling by receptors 
(TREM2, Dectin1, CCR2) that are key in promoting microglial survival and proliferation in the 
CNS (TREM2, Dectin1), hindering their effector function including responding to Aβ plaques 
(TREM2).46-48 SHIP1 also limits the production of granulocyte colony-stimulating factor (G-CSF) 
in vivo.21,49 Administration of G-CSF, or its co-administration with stem cell factor (SCF), have 
been shown to reduce disease severity in multiple murine Alzheimer's disease models.50,51 
Treatment with G-CSF has also been implicated to improve cognitive function in a small clinical 
trial in humans which explored G-CSF treatment in Alzheimer's patients.52 Given the significant 
preliminary data and the growing need for new Alzheimer's disease therapeutics, the development 
of new small molecule SHIP modulators which cross the blood brain barrier will likely be explored 
in this area in the near future. 
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1.7 SHIP Phosphatase Modulation with Small Molecules 
 Targeting the key inositol phosphatases and kinases present in PI3K cell signaling pathway, 
PI3K/PTEN/SHIP, has become a pharmaceutically appealing goal as these enzyme regulators are 
present at the top of the PI3K signaling chain, just inside the cell membrane. This allows for 
modulation of the signal near it's beginning but avoids issues with trying to influence and/or work 
with membrane bound proteins which can be time consuming and difficult. Development of PI3K 
modulators has had some success5,53,54 but unfortunately in many cases these successes have not 
been as widespread as was hoped, being only effective in small niche areas. This may be due to 
the need to target specific PI3K isoforms in order to ensure efficacy. As an alternative way to 
modulate PI3K signaling, interest has shifted to the development of SHIP agonists and antagonists 
to help regulate this system. In some ways SHIP represents a more specific target, as SHIP has 
only two main paralogs where as PI3K has many more. The development of these SHIP modulators 
will potentially increase the therapeutic advances for new treatments to counter or amplify PI3K 
signaling. In addition these small molecules can be used as probes to further interrogate the role 
of SHIP in the PI3K pathway and on cell signaling. 
 
1.8 SHIP Modulation: Small Molecule Agonists 
Aberrant activation of PI3K induces tumor growth attributed to the high concentrations of 
PI(3,4,5)P3 found within the cell. Acting as a negative regulator, SHIP1 can oppose the PI3K-AKT 
promoted signal by reducing the concentration of PI(3,4,5)P3. This is accomplished by catalyzing 
the hydrolysis of the 5’-phosphate from PI(3,4,5)P3, generating PI(3,4)P2. To increase the rate of 
hydrolysis, the development of SHIP agonists have become of interest to reduce PI3K over-
activation which is thought to lead to undesired cell division and excessive inflammation.  
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Small molecule agonists of SHIP1 and their effects on the PI3K pathway have been 
recently investigated by Anderson and co-workers with their initial identification of the naturally 
occurring sesquiterpene pelorol 1.1 (Figure 1.3) through a screen of crude marine 
invertebrates.5,41,55 Pelorol showed a two-fold increase of SHIP1 activation at 5µg/mL using 
recombinant purified SHIP1 in the malachite green phosphatase assay. To deliver more material 
for further biological studies, a nine step synthesis was developed for pelorol 1.1. This synthesis 
was then modified to provide a number of analogs, many of which were potent SHIP1 agonists. 
This study identified multiple new agonists, including AQX-016A 1.2 and AQX-MN100 1.3. The 
tolyl analog AQX-016A 1.2 was synthesized in a 6 step synthetic route starting from (+)-
sclareolide by Yang et al. and showed a six-fold increase in SHIP1 dephosphorylation in vitro at 
2 µM compared to pelorol which showed a two-fold increase at the same concentration.5,41,55 AQX-
016A 1.2 was found to be a selective SHIP1 agonist, selectively activating SHIP1 over SHIP2 by 
a factor of 5 in vitro.41 This molecule also was shown to inhibit degranulation and TNFα production 
in SHIP+/+ murine mast cells stimulated with IgE but no activity was observed with SHIP1-/- murine 
mast cells.5 When compared to the known anti-inflammatory agent dexamethasone, AQX-016A 
1.2 showed similar anti-inflammatory activity.55 Although showing potent agonistic activity 
selective for SHIP1, concerns with off-target issues led to the discontinuation of the development 
of this molecule. Specifically, the presence of a catechol (which is known to cause problems with 
metal binding and oxidation to the quinone methide in vivo, which can lead to undesired alkylation 
events) was a major concern. Later studies led to the development of AQX-MN100 1.3 by the 
removal of the hydroxyl moiety at C17.41,56 This compound was also shown to be a potent SHIP1 
agonist.  
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Figure 1.3: Structures of SHIP1 Agonists  
 
 
Interestingly, the activation of SHIP1 by AQX-MN100 1.3 was similar to AQX-016A 1.2 
(six-fold activation), but AQX-MN100 showed significantly improved toxicology due to the lack 
of the catechol.5 Evaluation of in vitro assays against multiple myeloma cells by Kennah et al. 
showed AQX-MN100 1.3 to be active and confirmed the role of a SHIP1 agonist as a potential 
therapeutic for hematopoietic cancer.25 Concerns about the water solubility of AQX-MN100 
became apparent, as the molecule is quite lipophilic and was difficult to dose orally. These poor 
solubility properties led Aquinox Pharmaceuticals to develop the amine derivatives of AQX-
MN100, 1.4 and 1.5. While these compounds were more water soluble the SHIP1 agonist activity 
was weaker.57 While racemic material was initially tested, separation of the two enantiomers 
interestingly showed that 1.5 was actually more active than 1.4. Further synthetic studies on these 
systems led to the development of the sulfone-containing analogs 1.6 and 1.7, which were hoped 
to have better pharmacodynamics properties.57,58  
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At some point Aquinox Pharmaceuticals halted development of the pelorol derivatives and 
instead focused on the seco-steroidal indene derivative containing an open B-ring, AQX-1125 1.8 
(Figure 1.4).59 This agonist shows a more moderate 20% activation of SHIP1 at 300 µM (compared 
to AQX-MN115 1.9 which shows a 77% increase in SHIP1 activity at 300 µM), however the 
excellent pharmacological properties and water solubility of AQX-1125 1.8 led to its advancement 
to phase II clinical trials as a treatment for asthma and COPD. These types of trials can be difficult 
to show efficacy, however, as the molecule must work on cells in the lungs which are often difficult 
to target. Insufficient efficacy was seen in the trial, and the molecule was moved to other trials 
against other inflammatory disorders. Eventually AQX-1125 1.8 was advanced to phase III clinical 
trials for interstitial cystitis/ bladder pain syndrome.60,61 Although not showing efficacy, AQX-
1125 1.8 has been the only compound targeting SHIP1 to advance to clinical studies and would 
provide a good standard for further development of a more potent agonist of SHIP1. 
 
Figure 1.4: Structure of SHIP1 Agonists AQX-1125 and AQX-MN115 
 
 
 
 
The identification of australin E 1.10 by Anderson and Mui in an isolate from the soft coral 
Cladiella sp. collected in Pohnpei was found to be another class of natural products to agonistically 
activate SHIP1 (Figure 1.5).5,62 This eunicellin diterpenoid showed an increase in SHIP1 activation 
by 12% at 100 µM, while the other isolates australin F 1.11 and G 1.12 showed no activation. This 
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seemed to indicate that the exocyclic olefin on the cyclohexane ring was key to the SHIP1 agonist 
activity that was observed.5  
 
 Figure 1.5: Eunicellin Diterpenoid and Cyclic Depsipeptide SHIP1 Agonists 
 
 
 
 
 
 
 
 
 
 
 
Further screening of natural product isolates provided yet another class of SHIP1 agonists: 
the cyclic depsipeptide turnagainolide B. Identified in a strain of Bacullus sp. cultured from a 
sediment sample collected from the sea floor, turnagainolide B 1.13 shows similar activity 
compared to AQX-MN100 1.3 (12% activation at 10 µM) however, a change in stereochemistry 
at the lactone moiety of turnagainolide A 1.14 showed no activation of SHIP1. 5,63  
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1.9 SHIP1 Modulation: Small Molecule Antagonists 
 Inhibition of SHIP inositol phosphatase activity using small molecule antagonists may 
have the potential to treat a number of diseases from cancer5,16,17 and diabeties,18,19 to 
cardiovascular disease and autoimmune disorders.2 Complicating the development of SHIP 
inhibitors is the presence of multiple SHIP isoforms in vertebrates. In blood and bone marrow 
(hematopoietic) cells, the major inositol 5'-phosphatase that generates PI(3,4)P2 is referred to as 
SHIP1. In other cells this function is typically performed by a similar phosphatase, SHIP2. 
Selective inhibitors are typically more desirable than pan-inhibitors to minimize side effects, but 
in some cases pan-inhibitors may also be of interest, especially in cases where resistance can 
manifest by the cells switching from the use of one paralog of SHIP to the other. 
 Some of the first SHIP antagonists disclosed were modified analogs of PI(3,4,5)P3 
containing a methylenephosphonate (like 1.15) or phosphorthioate (like 1.16 and 1.17) at the 5’ 
position. These molecules were developed by the Prestwich laboratory specifically to hinder SHIPs 
ability to hydrolyze the phosphate at the 5’ position (Figure 1.6).5,64 Evaluation of their effects on 
SHIP1 and SHIP2 showed 50% inhibition at 10 µM for SHIP1 with some inhibition also occurring 
for SHIP2.5 The differences in inhibition of SHIP1 and SHIP2 with these analogs was noteworthy 
as this was the first evidence that the two paralogs could be selectively inhibited. While these 
compounds are interesting academically, due to their highly charged nature they cannot cross cell 
membranes which limits their use as probes of the PI3K pathway in in vivo studies. 
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Figure 1.6: Analogs of PI(3,4,5)P3 
 
 
 
 
 
 In order to find small molecules with more drug like properties, the Kerr group performed 
a high-throughput screen of a library of compounds from the National Cancer Institute against 
SHIP1 using a fluorescence polarization assay. Brooks and co-workers found NSC23922 1.18 to 
have significant activity for the inhibition of SHIP1 (Figure 1.7).24 The activity was then confirmed 
using the colorimetric malachite green phosphatase assay.65 The α-amine isomer 3α-
aminocholestane 3AC 1.19 was found to be more active against one paralog of SHIP, SHIP1, with 
an inhibition of 50% at 10 µM and no inhibition of SHIP2.5 Interestingly, using 3AC 1.19, 
inhibition of SHIP1 was found to reduce the growth and increase apoptosis of the hematopoietic 
cancer cell lines AML (acute myelogenous leukemia) KG-1, murine C1498 leukemia cells, and 
multiple myeloma OPM2 cells with an IC50 at 10 µM, establishing that a delicate balance of both 
PI(3,4,5) and PI(3,4) are needed for cancer survival.5 Further studies showed that 3AC 1.19 
reduced tumor growth and increased survival in vivo in a mouse study where immunosuppressed 
mice were challenged with OPM2 cells, a multiple myeloma cell line. Some mice still showed 
significant tumor growth, however, and mice that developed cancer resistant to the treatment 
showed an increased expression of SHIP2 in the tumor cells which compensated for the SHIP1 
inhibtion.5,31 This study demonstrated the potential for the use of inhibitors that inhibit both SHIP1 
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and SHIP2 1.20,66 as the cancer cells cannot build resistance to the inhibitor as easily if both 
isoforms are inhibited. 
 
Figure 1.7: SHIP1 Aminosteroid Inhibitors 
 
 
 
 
 Additional SHIP inhibitors have been developed through three-dimensional modeling of 
mimics of PI(3,4,5)P3. This led to the discovery of the phosphorylated polyphenols 
biphenyl(2,3′,4,5′,6)P5 1.21, Bz(1,2,4,5)P4 1.22, and Bz(1,2,3,4)P4 1.23, which were identified to 
have a high homology to the phosphorylated inositol, and demonstrated activity as SHIP2 
inhibitors (Figure 1.8).5,67 The number and position of the phosphates present were shown to effect 
the inhibition of SHIP2. Biphenyl(2,3′,4,5′,6)P5 1.21 had an IC50 of 1.8 µM whereas Bz(1,2,4,5)P4 
1.22 exhibited an IC50 of 11.2 µM and Bz(1,2,3,4)P4 1.23 19.6 µM. However, due to the high 
polarity of these compounds they are unable to cross the cell membrane, so they cannot be utilized 
in in vivo studies.5,67  
 
Figure 1.8: SHIP2 Phosphorylated Polyphenol Inhibitors  
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Further work by Potter and coworkers, the biphenyl(2,3′,4,5′,6)P5 1.21 ligand (which is 
quite water soluble) facilitated the determination of a crystal structure of the SHIP2 phosphatase 
domain with the small molecule bound in the active site (Figure 1.9).68 While the entire SHIP 
protein could not be crystallized, a portion of the enzyme containing the phosphatase domain was 
able to form crystals which provided the data. This section of the enzyme was catalytically active 
as an inositol phosphatase. The x-ray structure revealed that a flexible loop of the SHIP2 protein 
acts as a P4-interactive motif (P4IM) where it can fold over the active site, facilitating the 
interactions leading to hydrolysis. With a crystal structure of the SHIP2 active site identified and 
having a high homology to SHIP1, the interactions with small molecule modulators can be 
rationally investigated to better design new SHIP inhibitors.5  
 
Figure 1.9: Crystal Structure of the SHIP2 Active Site 
 
 Workers at Astellas Pharmaceuticals identified the thiophene-based small molecule SHIP2 
inhibitor, AS1949490 1.24, which showed a high selectivity for SHIP2 and an IC50 of 0.62 µM 
(Figure 1.10).5,37 Upon treatment of L6 myoblasts with AS1949490 1.24, an increase in the 
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activation of AKT was observed, however, the inhibitor was found to only target the isoform of 
AKT, protein kinase B2 (AKT2), which plays a role in the insulin-signaling pathway.5,37,69 
AS1949490 1.24 was also found to control gluconeogenesis in vitro and in vivo.37 Astellas 
developed a second thiophene-based inhibitor AS1938909 1.25 which showed similar activity 
towards SHIP2 with greater selectivity.5,70 More recent studies suggest that AS1949490 1.24 may 
be a potential lead for new therapeutics for the treatment of Alzheimer’s disease.42  
 
Figure 1.10: SHIP2 Thiophene-Based Inhibitors 
 
 
 
 
 Further screening for SHIP2 antagonists led Neogenesis Pharmaceuticals to perform a 
high-throughput screen identifying the phenol-based inhibitor NGD61185 1.26 as a SHIP2 
inhibitor. The core of this system is based on salicylic acid, which is somewhat similar to the 
Astellas compounds from Fig. 1.10 (Figure 1.11). Other inhibitors identified by Neogenesis 
Pharmaceuticals include NGD61388 1.27 and NGD62448 1.28, which contain a highly 
functionalized pyrazole core. NGD61388 1.27 showed to be quite active with an IC50 of 1.1 µM 
against SHIP2.5,71 The most active compounds found in this screening campaign did not have their 
structures disclosed, however, so more active inhibitors have been found but their structures 
remain unknown. 
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Figure 1.11: SHIP2 Inhibitors Identified by Neogenesis Pharmaceuticals 
 
 
 
 
 
 Taking advantage of the inhibitors identified by Astellas and Neogenesis Pharmaceuticals, 
computational prediction software led to the discovery of the pyridine-based structure 1.29 as a 
SHIP2 inhibitor, as was determined by researchers at the University of Toyama and Kitasato 
University (Figure 1.12).5,72 This structure was based off the hydrogen bond functionality and 
orientation of the aromatic groups to get the conformation required for a biologically active SHIP2 
inhibitor.5 
 
Figure 1.12: SHIP2 Pyridine-Based Inhibitor 
 
 
 
 Interest in inhibitors that target both SHIP1 and SHIP2 led to a high-throughput screen 
performed by the Kerr group to identify pan-inhibitors for both paralogs of SHIP.5,31 The quinoline 
aminoalcohols 1.30 and 1.31 as well as the tyrptamine 1.32 were identified (Figure 1.13). 
Tryptamine 1.32 showed an IC50 of 4-5 µM against SHIP1 and 9-10 µM against SHIP2. Each 
inhibitor was evaluated for its ability to inhibit SHIP1 and SHIP2 in vitro. All three molecules also 
showed activity against the multiple myeloma cell lines RPM18226, U266, and OPM2 through 
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inhibition of SHIP1. Activity was also observed against the breast cancer cell lines MDA-MB-231 
and MCF-7, which do not express SHIP1 (the SHIP1 selective inhibitor 3AC showed no activity), 
reducing the cell survival and proliferation using the pan-inhibitors.5 
 
Figure 1.13: SHIP1/2 Pan-Inhibitors 
 
 
 
 
 Additional high throughput screening by the De Cammili group at Yale led to the 
identification of two new classes of SHIP inhibitors: the triazolo[3,4-b][1,3,4] thiadiazoles 1.33, 
1.34 and 1.35 and the benzylic amines 1.36, 1.37 and 1.38 (Figure 1.14).73 These compounds not 
only showed inhibition of SHIP1 and SHIP2, but also showed inhibition of other 5'-inositol 
phosphatases that are not structurally related to SHIP, namely OCRL and, in the case of the 
benzylic amines, both OCRL and synaptogenin SJ1. This is unusual as most of the other inhibitors 
mentioned previously do not inhibit the other 5'-inositol phosphatases. The promiscuity of the 
inhibition has likely limited the use of these compounds for further studies.  
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Figure 1.14: SHIP Inhibitors Discovered at Yale University 
 
 
 
 
 
 
 
1.10 Summary 
 The development of isoform specific PI3K inhibitors for the treatment of inflammatory 
disease and cancer has proven difficult and provided only mixed results. This has led to the 
exploration of alternative strategies to modulate signaling in this pathway, including targeting the 
inositol phosphatase SHIP. This mode of attack is not without challenges, however, as multiple 
isoforms of SHIP are known and SHIP has also been shown to be both an activator and an 
antagonist of PI3K signaling depending on the environment. Despite these potential issues, a 
number of approaches has led to the identification of SHIP antagonists and agonists. These 
molecules have been shown to be not only useful in probing the role of SHIP in cell signaling, but 
have also been used to provide information on potential treatments for a variety of disorders from 
cancer to inflammation to Alzheimer's disease. Given the common role PI3K signaling plays in 
many of these diseases, further study of small molecule modulators of SHIP appears to be justified. 
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Abstract 
SHIP is a key regulator in the PI3K cell signaling pathway, influencing the phosphorylation 
patterns of inositol phospholipids intercalated in the cell membrane which act as second 
messengers helping transmit signals from outside the cell to the nucleus. Misregulation of SHIP 
disrupts this signaling, causing changes in many aspects of cellular physiology. These changes 
have been implicated in a number of human disorders ranging from cell growth diseases (cancer), 
immune response diseases (autoimmune disease), chronic neurodegenerative diseases 
(Alzheimer’s) and obesity. Since the SHIP enzyme may play a role in the pathogenesis of these 
conditions, regulation of SHIP with small molecules is an attractive approach to ameliorate any 
aberrant signaling. Attempts to modulate SHIP activity with small molecules has led us to 
investigate the synthesis of new aminosteroid SHIP inhibitors. These molecules may then be used 
to further evaluate the role SHIP plays in this signaling pathway. These studies may also aid in 
determining the key structure-activity relationships necessary for increased potency and selectivity 
for inhibition of a specific paralog of SHIP (SHIP1 over SHIP2).  
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2.1 Introduction 
 The phosphatase SHIP1 is expressed and utilized in hematopoietic cells, while a paralog 
enzyme (SHIP2) is utilized in other cells. This difference provides a potentially selective way of 
targeting PI3K signaling in these specific cell types. The regulation of the SHIP1 enzyme has been 
shown to play an important role in the cellular physiology of blood and bone marrow cells,1-3 
endothelial cells,4 and embryonic cells5 by the effects it invokes on the PI3K signaling pathway. 
Understanding the role of SHIP modulation may lead to the development of possible therapeutic 
treatments for a wide spectrum of human disorders6 ranging from cancer,7,8 autoimmune diseases,9 
Alzheimer’s,10 as well as obesity.11 However, isolation and use of small molecule SHIP modulators 
is complicated by the presence of several isoforms of the SHIP enzyme in vertebrates. The 
development of selective SHIP inhibitors may have advantages over pan-inhibitors to minimize 
any side effects in these potential treatments. In order to take advantage of paralog specific 
inhibition, specific SHIP inhibitors targeting each paralog of SHIP are needed. This can be 
challenging, as the two enzymes are highly homologous, however recently Astellas divulged some 
SHIP2 specific inhibitors,12,13 so specific inhibition of SHIP isoforms has been shown to be 
possible. 
Utilizing a fluorescence polarization assay to detect inhibition activity against recombinant 
SHIP1, a high-throughput screen identified the aminosteroid NSC23922 2.1 (Figuer 2.1) from a 
library of compounds available from the National Cancer Institute. NSC23922 was actually a 
mixture of the 3a and 3b isomers, but further studies showed that the α-isomer,	 3α-aminocholestane	3AC	2.2,	was significantly more active (Figure 2.1).14 The 3a-aminocholestane 
2.2 showed 50% inhibitory activity against the SHIP1 enzyme at 10 µM with inhibitory activity 
still observed at 2 µM against 0.1 µg of recombinant SHIP .9,14  
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 Figure 2.1: Structure of NSC23922 2.1, 3AC 2.2, and Steroid Numbering System 
 
Further evaluation using the colorimetric Malachite Green assay proved 3AC 2.2 to be a 
selective inhibitor of SHIP1 at 1mM concentration with no inhibition detectable for two other 
inositol phosphatases, SHIP2 and PTEN, which also hydrolyze PI(3,4,5)P3 (Figure 2.2). This 
selectivity allows for a greater understanding of the role of SHIP1 in the PI3K cell signaling 
pathway with less risk of off target effects, as it has been shown that inhibition of PTEN can be 
detrimental as it acts as a tumor suppressor, inhibiting tumor growth and cell malignancies.15-17 
 
Figure 2.2: 3AC is a Selective SHIP1 Inhibitor based on Malachite Green Assay Results9,14 
 
 
 
 
 
 
With in vitro data supporting 3AC 2.2 to be a selective SHIP1 inhibitor, in vivo testing in 
mice was undertaken to show whether or not small molecule inhibition with 3AC showed effects 
in an animal. Adult mice treated with 60 µM 3AC 2.2 daily for 7 days showed to have a similar 
increase in Mac1+Gr1+ myeloid immunoregulatory (MIR) cells comparable to SHIP knockout 
mice, whereas vehicle mice had no increased response (Figure 2.3).9,18 Increases in MIR cells in 
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peripheral lymphoid tissues suppresses allogeneic T cell responses, which is a potential method to 
treat Graft versus host disease (GvHD) and reduce bone marrow and organ transplant 
rejection.9,14,18-20 A similar modified immune system was observed in SHIP1 knockout mice, 
which accept mismatched bone marrow grafts without rejection.21 This study was important as it 
showed that the aminosteroids possessed adequate pharmacodynamic properties to be effective in 
animal model systems. 
 
Figure 2.3: Mac1+Gr1+ Myeloid Immunoregulatory (MIR) Cells in Spleen (A) and Lymph Node 
(B) of Mice Treated with 3AC 2.2 (Compound), Vehicle (Ethanol), and Unmanipulated Control 
(Normal)9,14  
 
 
 
 
 
 
 
 
 
 
More evidence of SHIP modulation in vivo was observed when mice treated with 3AC 2.2 
showed a 4- to 5-fold increase in circulating granulocytes in peripheral blood similar to that of 
SHIP-/- mice (Figure 2.4).9,22 However, unlike SHIP knockout mice which show lung defects which 
A 
B 
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result in the development of pneumonia, mice treated with NSC23922 2.1 appeared to have normal 
lung function. Mice treated with 3AC 2.2 did not show any toxic side-effects, nor was there an 
increase in mortality or body weight fluctuation (Figure 2.5).9,14,18,19,22 
 
Figure 2.4: SHIP1 Inhibition Increases Circulating Granuocyte/Neutrophil Numbers9,14 
 
 
 
 
 
Figure 2.5: Induction of Lung Pneumonia in SHIP-Deficient Adult Mice (A-C). SHIP Inhibition 
Does Not Induce Myeloid-Associated Lung Pneumonia (D-F). No Reduction of Body Weight When 
Treated with 3AC 2.2 (G).9,14  
 
 
 
 
 
As SHIP can both activate and inhibit PI3K signaling depending on the environment, there 
was some concern that SHIP inhibitors may act to facilitate tumor growth. To alleviate any concern 
of potential blood cell cancer promotion and/or enhanced survival, 3AC 2.2 treatment of several 
cancer cell lines was explored. Both the SHIP1 expressing KG-1 AML cell line and osteosarcoma 
cells that show no expression of SHIP1 were evaluated in vitro (Figure 2.6).9 Cell growth and 
A B
 
C
 
D
 
E
 
F 
G 
 35 
survival decreased in the KG-1 cells but no effect was observed on the osteosarcoma cells. Murine 
C1498 leukemia cells were also observed to be responsive to 3AC 2.2 upon treatment, but K562 
leukemia cells that only express SHIP2 and PTEN showed no observable effect.9 SHIP1 inhibition 
was also shown to cause cell death in multiple myeloma (MM) cell lines using 3AC 2.2 as the 
SHIP1 inhibitor.9 It is evident that SHIP1 inhibition through small molecule 3AC 2.2 treatment 
can be a potential for human blood therapeutic treatments as inhibition leads to a decrease in AKT 
activation and apoptosis.    
 
Figure 2.6: Increased 3AC 2.2 Concentration Promotes Cell Death of SHIP1 Expressing KG-1 
AML Cells and C1498 Leukemia Cells. No Apoptosis Observed for K562 Leukemia Cells Only 
Expressing SHIP2 and PTEN.9  
 
 
 
 
 
 
 
Interestingly, SHIP1 has recently been discovered to play a role in trained immunity and 
improved cell response to infection through increased activation of the PI3K/AKT/mTOR 
signaling pathway.23 In vitro studies identified macrophages from SHIP1-deleted myeloid cells to 
have an increase in proinflammatory cytokine production through β-glucan induced training when 
exposed to a lethal dose of lipopolysaccharides.23 This increased proinflammatory response was 
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also observed when bone marrow derived macrophages (BMDM) trained with β-glucan were 
administered 3AC 2.2 before being treated with lipopolysaccharides. The cell response showed a 
dose-dependent increase in TNFα	production	(Figure 2.7).23  
 
Figure 2.7: Increasing TNFα	Production	from	Bone	Marrow	Derived	Macrophages	Trained	with	Increasing	Concentrations	of	3AC	2.2	23 
 
 
 
 
 
 
 
In vivo evaluation of 3AC’s 2.2 ability to help boost a trained immunity response to 
infectious conditions showed that mice treated with 3AC 2.2 twice daily on consecutive days 
followed by exposure to a low dose of Candida albicans followed by a 7-day period before being 
injected with a lethal dose of the same fungus proved that mice trained with the fungus while being 
administered the SHIP1 inhibitor 3AC 2.2 had a higher survival rate (Figure 2.8).23 Mice not 
trained with the Candida albicans fungus but still administered 3AC 2.2 showed no significant 
increase in survival compared to the control. Mice primed with the fungus but not administered 
3AC 2.2 had a higher survival rate compared to the control but not greater than the 3AC 2.2 
trained.23 These results were attributed to the role of SHIP1 in the immune response, where loss 
of SHIP1 function leads to oversensitive immune cells.24 By using a transient inhibition of SHIP1, 
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the immune cells can be hypersensitized for a short time, and then trained with only a mild 
challenge to target foreign cell like cancer cells or a fungal infection.  
 
Figure 2.8: Survival Curve of 3AC 2.2 Primed Mice Trained with Candida albicans23 
 
  
 
 
 
 
 
2.2 Objectives 
 
More recent studies on 3AC 2.2 showed that while the compound was still selective for 
SHIP1, some inhibition of SHIP2 was being observed, with 3AC 2.2 only showing an 
approximately 3-fold selectivity for SHIP1. While this may have been the result of the use of a 
different source of the SHIP2 enzyme (the new source was recombinant human SHIP2 instead of 
the original enzyme, which was derived from a murine source), it may also be due to the testing 
of a single isomer of the aminosteroid, as the initial testing which showed selective inhibition was 
performed on NSC23922 2.1 which is a mixture of isomers (Figure 2.9). Therefore the b-isomer 
of NSC23922 2.3 could potentially have been mischaracterized, and should it be a potent SHIP1 
inhibitor leading to a reassessment of these inhibitors (Figure 2.9). To investigate these issues, the 
resynthesis of both 2.2 and 2.3, as well as the reformulation of the original NSC23922 2.1 was 
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undertaken so that all three could be tested against SHIP1 and SHIP2 side by side under exactly 
the same assay conditions. 
 
 
Figure 2.9: Structures of NSC23922 2.1, the α-isomer 3AC 2.2, and β-isomer 2.3.  
 
 
Furthermore, an investigation of structure-activity relationships in aminosteroids was 
undertaken to determine which functionality was necessary for potency and SHIP1 selectivity. The 
focus of this study was to increase the potency of the SHIP inhibitors to a sub-micromolar level. 
Additionally, 3AC 2.2 has poor water solubility properties and therefore some efforts were made 
into developing analogs that not only had increased potency, but also increased water solubility. 
Structural information about SHIP would greatly facilitate these studies, but unfortunately no 
crystal structure of SHIP1 has been determined. Initially, the priority was to increase water 
solubility. This was achieved by removing the greasy aliphatic carbon chain at C17. Removal of 
the C17 side chain resulted in the more potent and more water soluble SHIP inhibitors K185 2.4 
and K118 2.5, but interestingly these molecules target both SHIP1 and SHIP2, with the SHIP1 
selectivity being lost (Figure 2.10).25 This revelation made it clear that the C17 side chain was 
important in determining selectivity between the two paralogs.  
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 Figure 2.10: Structure and Selectivity of 3AC 2.2 and Tailless Derivatives K185 2.4 and K118 
2.5.25(Inhibition of SHIP1 and SHIP1 was determined using the malachite green assay at 1mM 
concentration). 
 
 
 With interest in further understanding the active site of SHIP1, the SHIP2 crystal structure 
described by Potter and coworkers26 was modified by threading the SHIP1 amino acid sequence 
into the structure with hopes that the high homology between SHIP1 and SHIP2 would construct 
a reasonable model of the SHIP1 phosphatase active site. This model could then be used for 
evaluation of small molecule docking in the active site (Figure 2.11). The Potter x-ray structure 
(PDB ID = 4A9C) is missing much of the enzyme including the SH2 and PH protein-protein 
recognition domains as well as the C2 domain (SHIP is a 145 kDa protein, the structure is only 73 
kDa), but does contain the phosphatase domain and is catalytically active. This model revealed 
that the P4-interactive motif (P4IM) flexible loop could fold over the active site, facilitating the 
phosphate hydrolysis by interacting with the alkyl chains of PI(3,4,5)P3. This same area may be 
where the C17 carbon chain of 3AC 2.2 binds to achieve SHIP1 selectivity, as the SHIP1 amino 
acid sequence is less polar than that of the SHIP2 sequence in this area of the enzyme. When the 
C17 chain was removed no interaction between the tail and loop can occur, leading to the 
unselective inhibition of SHIP1 and SHIP2. 
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Figure 2.11: Model of the SHIP1 Active Site and Docking of 3AC 2.2 
 
 
Interest in the effects associated with the substituents at the C17 position (Figure 2.12) has 
led to the investigation of new aminosteroids containing nonpolar ethers of various sizes at C17 
(2.6, 2.7, 2.8, 2.9), which will allow us to explore the effect of substituent size on SHIP1/SHIP2 
selectivity as well as evaluate water solubility. These studies may also lead to the development of 
more potent SHIP inhibitors, as proper functionalization of the C17 side chain may lead to better 
interaction with the enzyme and increased binding and potency. 
 
Figure 2.12: C-17 Ether Derivatives of 3AC 
 
 
 Additionally, this investigation has led to the synthesis of the alkynyl ether 2.10 (Figure 
2.13). The alkyne functionality provides an attachment point through click chemistry with 
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azides,27,28 which may be useful for the synthesis of fluorescent compounds which may provide a 
means of following the molecule in its interactions with SHIP and other receptors. Additionally, 
the alkyne 2.10 may be used in determining if the aminosteroid is binding to other proteins via an 
azide labelled biotin-streptavidin in pull-down experiments with cell lysates. 
 
Figure 2.13: C-17 Alkynyl Ether Derivative of 3AC 2.10 
 
 
2.3 Results and Discussion 
Synthesis of the C3α-aminosteroid 2.2 
The synthesis of the C3α-aminosteroid 2.2 was performed to provide material for testing 
for both the α-azide 2.13 and the mixture of a and b isomers 2.1. Starting from the commercially 
available dihydrocohlesterol 2.11, formation of the mesylate 2.12 was accomplished in 93% yield 
with methanesulfonyl chloride (MsCl) and triethylamine (Et3N) (Scheme 2.1). Formation of the 
mesylate produced a good leaving group, allowing for an SN2 displacement with sodium azide 
(NaN3) in dimethylformamide (DMF) to generate the α-azide isomer 2.13 in 80% yield. This 
methodology proved more effective than a direct Mitsunobu reaction on alcohol 2.11 previously 
utilized in the laboratory. Staudinger reduction29,30 using triphenylphosphine, tetrahydrofuran 
(THF), and excess water on azide 2.13 provided the 3α-amine 2.14 in 55% yield. This route for 
the reduction allows for milder and safer conditions, compared with the previously used lithium 
aluminum hydride reduction. Formation of the 3α-amine hydrochloride salt 3AC 2.2 was achieved 
-Cl+H3N H
H H
H
2.10
O
17
H
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by bubbling dry hydrogen chloride gas into a solution of 2.14 in diethyl ether (Et2O) providing the 
α-salt 2.2 in 65% yield.31  
 
Scheme 2.1: Synthesis of 3AC 2.2 
 
Synthesis of the C3b-aminosteroid 2.3 
Synthesis of the 3β-amino isomer 2.3 began by first performing a Mitsunobu reaction32 
with triphenylphosphine, diisopropyl azodicarboxylate (DIAD), and methyl iodide on 
commercially available dihydrocholesterol 2.11 producing 3α-iodo-5α-cholestane 2.15 in 90% 
yield (Scheme 2.2). An SN2 reaction with on the iodide with sodium azide in dimethylformamide 
was then performed to provide 3β-azido-5α-cholestane 2.16 in 82% yield. The Staudinger 
reduction reaction was again utilized to reduce azide 2.16 to give the 3β-amine 2.17 in 85% yield. 
Formation of the 3β-amine hydrochloride salt 2.3 was achieved by bubbling dry hydrogen chloride 
gas into a solution of 2.17 in diethyl ether (Et2O) providing the β-salt 2.3 in 83% yield.  
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Scheme 2.2: Synthesis of β-amine Isomer 2.3 
 
Synthesis of β-amine salt K118 2.5 
Aminosteroid 2.5 was synthesized from epiandrosterone 2.18 by initially performing a 
Wolff-Kishner33 reduction to generate alcohol 2.19 in 95% yield (Scheme 2.3). A Mitsunobu 
reaction was then performed using triphenylphosphine, diisopropyl azodicarboxylate (DIAD), and 
methyl iodide to produce iodide 2.20 in 60% yield. Using sodium azide in dimethylformamide, a 
SN2 reaction was performed on 2.20 to give azide 2.21 in 76% yield. Again, utilizing the mild 
Staudinger reduction with triphenylphosphine, tetrahydrofuran (THF), and excess water on azide 
2.21 produced the amine 2.22 in 95% yield. Finally, bubbling dry hydrogen chloride gas into a 
solution of 2.22 and diethyl ether provided the amine hydrochloride salt 2.5 in 93% yield.  
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Scheme 2.3: Synthesis of K118 2.5 
 
 
Synthesis of α-isomer aminosteroid analogs 2.6, 2.7, 2.8 
With interest in the ether formation at C17, epiandrosterone 2.18 was utilized for the 
starting material. Formation of the 3b-mesylate 2.23 was achieved in 91% yield (Scheme 2.4). An 
SN2 reaction using sodium azide in dimethylformamide then provided azide 2.24 in 88% yield. 
The pure α-azido ketone 2.24 was diastereoselectively reduced to the α-azido alcohol 2.25 using 
sodium borohydride (NaBH4) in methanol in 77% yield.  
 
Scheme 2.4: Synthesis of Alcohol Intermediate 2.25 
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With similar stereoselective reductions at C17 having been reported,34,35 the selectivity is 
most likely due to the presence of the axial methyl group at C13 hindering the β-face and forcing 
the pseudoequatorial hydride delivery to the α-face of the ketone 2.24, producing the C17 b-
alcohol 2.25 as the sole observed product (Figure 2.14).  
 
Figure 2.14: Possible Mechanistic Approach for Hydride Delivery 
 
 
 
 
 
 
The formation of the methyl ether 2.26, ethyl ether 2.27, and n-butyl ether 2.28 was 
achieved through a Williamson ether synthesis,36 utilizing a number of alkyl halide electrophiles 
(Scheme 2.5). This gave yields of 54%, 80%, and 70% with methyl iodide, ethyl bromide and butyl 
bromide respectively. The newly synthesized 3α-azido C17-ethers could be readily reduced to the 
3α-amines 2.29, 2.30, and 2.31 using the Staudinger reduction conditions with yields of 89%, 76%, 
and 78%, respectively. Formation of the 3α-amine ether hydrochloride salts 2.6, 2.7, and 2.8 was 
then achieved by reaction with dry hydrogen chloride gas, producing yields of 72%, 82%, and 
72%, respectively. These compounds are now undergoing testing for their ability to inhibit SHIP1 
and SHIP2 in vitro.  
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Scheme 2.5: Synthesis of Ether derivatives 
 
 
 
 
 
 
 
Synthesis of C3α-aminocholestane alkynyl ether aminosteroid analog 2.10 
With a useful synthetic route for the ether analogs in place, attention was turned to the 
synthesis of the alkynyl ether 2.10 (Scheme 2.6). Utilizing the key intermediate alcohol 2.25 
(derived from epiandrosterone) with the mesylate from 10-undecyn-1-ol37 2.32 provided azide 
2.33 in 80% yield. Following the previously identified route for reduction of the azide 2.33 by 
Staudinger reduction produced amine 2.34 in 62% yield. Bubbling dry hydrogen chloride gas into 
a solution of 33 and diethyl ether generated the alkynyl ether hydrochloride salt 2.10 in 35% yield. 
The lower yield of the salt in this case may be due to the greater solubility of the long chain alkyne 
amine salt in organic solvents. 
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Scheme 2.6: Synthesis of Alkyne Ether Derivative 2.10 
 
 
 
 
 
 
 
2.4 Conclusion 
 The successful synthesis of the α-isomer 2.2 and the β-isomer 2.3 allows for the further 
evaluation of their activity and selectivity of these compounds to provide further insight into these 
small molecule inhibitors of SHIP. Along with the isomers of NSC29322 2.1, the original isomer 
mixture identical to NSC29322 2.1 (Scheme 2.7), as well as the α-azide 2.13 and the  β-iodide 2.16 
will be tested for activity. Along with these molecules, the newly synthesized aminosteroids 
containing ethers at C-17 will be evaluated for SHIP activity as well. Depending on the results of 
the assay studies, a variety of compounds could easily be accessed by utilizing the etherification 
process. These studies will provide information about the structure activity relationships and may 
also lead to more potent SHIP inhibitors. 
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Scheme 2.7: Original Mixture of NSC29322 2.1 
 
 
 The synthesis of alkyne ether 2.10 was also accomplished. This alkyne functionality in this 
molecule allows for its use in pull down assay studies through the use of click chemistry. Detailed 
information about the aminosteroid scaffolds selectivity towards not only SHIP but a wide range 
of other proteins, may now be examined. The alkyne 2.10 may also be utilized to incorporate 
fluorescent tags on the inhibitor. These fluorescent molecules may be also used to evaluate the 
binding of the aminosteroid to different proteins.  
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2.5 Experimental 
General Methods: All anhydrous reactions were run under a positive pressure of argon. All 
syringes, needles, and reaction flasks required for anhydrous reactions were dried in an oven and 
cooled under an N2 atmosphere or in a desiccator. Dichloromethane and THF were dried by 
passage through an alumina column following the method of Grubbs (Pangborn, A. B.; Giardello, 
M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518). All other 
reagents and solvents were purchased from commercial sources and used without further 
purification.  
Analysis and Purification. Analytical thin layer chromatography (TLC) was performed on 
precoated glass backed plates (silica gel 60 F254; 0.25 mm thickness). The TLC plates were 
visualized by UV illumination and by staining. Solvents for chromatography are listed as 
volume:volume ratios. Flash column chromatography was carried out on silica gel (40-63 μm). 
Melting points were recorded using an electrothermal melting point apparatus and are uncorrected. 
Elemental analyses were performed on an elemental analyzer with a thermal conductivity detector 
and 2 meter GC column maintained at 50 °C. 
Identity. Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were 
recorded at 300 or 400 MHz and 75 or 100 MHz respectively. The chemical shifts are given in 
parts per million (ppm) on the delta (δ) scale. Coupling constants are reported in hertz (Hz). The 
spectra were recorded in solutions of deuterated chloroform (CDCl3), with residual chloroform (δ 
7.26 ppm for 1H NMR, δ 77.23 ppm for 13C NMR) or tetramethylsilane (δ 0.00 for 1H NMR, δ 
0.00 ppm for 13C NMR) as the internal reference. Data are reported as follows: (s = singlet; d = 
doublet; t = triplet; q = quartet; p = pentet; dd = doublet of doublets; dt = doublet of triplets; td = 
triplet of doublets; tt = triplet of triplets; qd = quartet of doublets; ddd = doublet of doublet of 
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doublets; br s = broad singlet). Where applicable, the number of protons attached to the 
corresponding carbon atom was determined by DEPT 135 NMR. Infrared (IR) spectra were 
obtained as thin films on NaCl plates by dissolving the compound in CH2Cl2 followed by 
evaporation or as KBr pellets. 
 
 
 
5-cholestane-3-ol-3-methanesulfonate (2.12)38 
Lit. Ref.: Sugandhi, E. W.;  Slebodnick, C.;  Falkinham, J. O.; Gandour, R. D., Synthesis and 
antimicrobial evaluation of water-soluble, dendritic derivatives of epimeric 5α-cholestan-3-amines 
and 5α-cholestan-3-yl aminoethanoates. Steroids 2007, 72, 615-626. 
 
A solution of 5α-cholestan-3β-ol 2.11 (0.500 g, 1.29 mmol) in 13 mL DCM was cooled to 0 ˚C. 
Et3N (0.360 mL, 2.58 mmol) was added to the cooled solution followed by slow addition of MsCl 
(0.120 mL, 1.55 mmol). The reaction mixture was stirred for approximately 30 min before 12 mL 
of water was added and the aqueous phase separated and extracted with DCM (2 x 12 mL). The 
organic extracts were collected and washed with brine (2 x 12 mL), dried over Na2SO4, filtered 
and concentrated. The residue was purified by column chromatography on silica gel using 100% 
hexanes as the eluent to produce 5α-cholestane-3β-ol-3-methanesulfonate 2.12 (0.444 g, 93%). 
m.p. = 107-110 ˚C; TLC Rƒ = 0.68 (hexane:EtOAc, 3:1); 1H NMR (400 MHz, CDCl3) δ 4.67-4.54 
(m, 1H), 3.01 (s, 3H), 1.93-2.10 (m, 2H), 1.72-1.86 (m, 3H), 1.61-1.71 (m, 2H), 1.57-1.60 (m, 1H), 
1.54-1.56 (m, 4), 1.42-1.53 (m, 3H), 1.29-1.37 (m, 4H), 1.19-1.28 (m, 3H), 1.04-1.17 (m, 6H), 
MsO
2.12
H
H
H H
H
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0.93-1.03 (m, 3H), 0.89 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 1.8 Hz, 3H), 0.85 (d, J = 1.8 Hz, 3H), 0.82 
(s, 3H), 0.64 (s, 3H). 
 
 
 
3-azido-5-cholestane (2.13)14,38 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
5α-cholestane-3β-ol-3-methanesulfonate 2.12 (2.12 g, 4.55 mmol) was dissolved in 45 mL DMF 
and stirred at room temperature. NaN3 (0.592 g, 9.10 mmol) was added and the reaction mixture 
was heated to 90˚C. After approximately 5 h the reaction was allowed to cool to room temperature 
and 45 mL of water was slowly added to quench the reaction. The reaction mixture was extracted 
with ethyl acetate (3 x 14 mL) and the combined organic extracts were washed with water (3 x 14 
mL), brine (3 x 14 mL), dried over sodium sulfate, filtered and concentrated. Purification with 
column chromatography on silica gel using 100% hexanes as the eluent provided 3α-azide 2.13 
(1.73 g, 80%). m.p. = 44-50 ˚C; TLC Rƒ = 0.61 (hexane); 1H NMR (400 MHz, CDCl3) δ 3.88 (t, J 
= 2.8 Hz, 1H), 1.96 (dt, J = 12.2, 3.0 Hz, 1H), 1.86-1.76 (m, 1H), 1.73-1.65 (m, 2H), 1.64-1.61 
(m, 1H) 1.59-1.54 (m, 3H), 1.53-1.49 (m, 2H), 1.48-1.45 (m, 2H), 1.43-1.40 (m, 1H), 1.39-1.35 
(m, 1H), 1.34-1.30 (m, 3H), 1.29-1.23 (m, 2H), 1.22-1.17 (m, 3H), 1.16-1.06 (m, 5H), 1.05-0.93 
(m, 3H), 0.90 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 1.9 Hz, 3H), 0.85 (d, J = 1.9 Hz, 3H), 0.78 (s, 3H), 
N3
2.13
H
HH
H
H
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0.77-0.69 (m, 1H), 0.65 (s, 3H). Anal calcd for C27H47N3: C, 78.39; H, 11.45; N, 10.16. Found: C, 
78.22; H, 11.64; N, 10.27. 
 
 
 
3-Amino-5-cholestane (2.14)14,38 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
To a solution of α-azide 2.13 (1.21 g, 2.91 mmol) in 15 mL of anhydrous THF was added 
triphenylphosphine (1.15 g, 4.37 mmol). The solution was heated to 50˚C with the addition of 
water (0.100 mL, 5.55 mmol) in excess and stirred overnight (approx. 17 h). The reaction mixture 
was concentrated, and the residue purified by silica gel column chromatography, initially using 
90:10 DCM:MeOH solution as the eluent, then 90:9:1 DCM: methanol: 40% aq. ammonium 
hydroxide as the eluent to produce the α-amine 2.14 (0.621 g, 55%) as a white solid. m.p. = 71-
76˚C; TLC Rƒ = 0.38 (DCM:MeOH:NH4OH, 90:9:1); 1H NMR (300 MHz, CDCl3) δ 3.14 (bs, 
1H), 1.96 (dt, J = 6.1, 3.4 Hz, 1H), 1.88-1.70 (m, 2H), 1.69-1.64 (m, 1H), 1.63-1.58 (m, 1H), 1.62-
1.51 (m, 6H), 1.50-1.42 (m, 4H), 1.41-1.35(m, 4H), 1.29-1.16 (m, 5H), 1.15-1.02 (m, 6H), 1.01-
0.90 (m, 4H), 0.88 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 1.8 Hz, 3H), 0.83 (d, J = 1.6 Hz, 3H), 0.78 (s, 
3H), 0.65 (s, 3H). 
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3-Amino-5-cholestane hydrochloride 3AC (2.2)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
α-amine 2.14 (0.621 g, 1.60 mmol) was dissolved in 20 mL of Et2O and allowed to stir while dry 
HCl gas was purged into the reaction mixture by the reaction of concentrated sulfuric acid and 
sodium chloride. During this time a precipitate formed. After approx. 5 min the reaction mixture 
was filtered and the white precipitate was collected and dried under vacuum producing the α-amine 
hydrochloride salt 2.2 (0.443 g, 65%) as a white solid. m.p. = 253˚C (dec.); 1H NMR (300 MHz, 
CDCl3) δ 8.47 (bs, 3H), 3.61 (bs, 1H), 1.94 (d, J = 10.3 Hz, 1H), 1.86–1.78 (m, 2H), 1.66–1.61 
(m, 2H), 1.56–1.43 (m, 6H), 1.40–1.30 (m, 7H), 1.27– 1.25 (m, 1H), 1.21–1.17 (m, 4H), 1.13–1.10 
(m, 4H), 1.04–0.93 (m, 5H), 0.90 (s, 3H), 0.86 (d, J = 1.4 Hz, 3H), 0.84 (d, J = 1.4 Hz, 3H), 0.78 
(s, 3H), 0.63 (s, 3H); Anal calcd for C27H50ClN: C, 76.46; H, 11.88; N, 3.30.  Found: C, 76.18; H, 
11.76; N, 3.63. Anal calcd for C27H50ClN: C, 76.46; H, 11.88; N, 3.30.  Found: C, 76.70; H, 11.88; 
N, 3.50. 
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3-Iodo-5-cholestane (2.15)14,39 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
To a solution of 5α-cholestan-3β-ol 2.11 (2.00 g, 5.15 mmol) and triphenylphosphine (1.48 g, 5.67 
mmol) in 28 mL benzene was added a solution of DIAD (1.10 mL, 5.67 mmol) in 12 mL of 
benzene dropwise. The resulting yellow solution was stirred at room temperature for 15 min before 
a solution of iodomethane (0.350 mL, 5.67 mmol) in 12 mL of benzene was slowly added 
dropwise. The reaction mixture was allowed to stir continuously for approx. 6 h before addition of 
another equiv of triphenylphosphine, DIAD, and iodomethane. The reaction was allowed to stir 
overnight for approx. 24 h before it was concentrated under reduced pressure, and purified by 
chromatography on silica gel using 100% hexanes as the eluent to afford the α-iodide 2.15 (2.32 
g, 90%) as an off white solid. m.p. = 105-109 ˚C; TLC Rƒ = 0.92 (hexane:EtOAc, 3:1); 1H NMR 
(400 MHz, CDCl3) δ 4.94-4.91 (m, 1H), 2.10-1.94 (dt, J = 12.0, 2.8 Hz, 1H), 1.93-1.88 (dt, J = 
14.8, 2.5 Hz, 1H), 1.87-1.75 (m, 1H), 1.74-1.69 (m, 1H), 1.68-1.65 (m, 2H), 1.64-1.60 (m, 1H), 
1.59-1.53 (m, 3H), 1.52-1.49 (m, 1H) 1.48-1.46 (m, 1H), 1.45-1.39 (m, 1H), 1.38-1.31 (m, 4H), 
1.30-1.28 (m, 1H), 1.27-1.25 (m, 1H), 1.24-1.18 (m, 3H), 1.17-1.06 (m, 5H), 1.05-0.94 (m, 4H), 
I
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0.90 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 1.9 Hz, 3H), 0.85 (d, J = 1.9 Hz, 3H), 0.79 (s, 3H), 0.65 (s, 
3H); Anal calcd for C27H47I: C, 65.04; H, 9.50. Found: C, 65.09; H, 9.74. 
 
 
 
 
3-Azido-5-cholestane (2.16)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
A suspension of α-iodide 2.15 (2.25 g, 4.52 mmol) and NaN3 (2.94 g, 45.2 mmol) in 113 mL DMF 
was warmed to 90˚C in a round bottom flask. After approx. 2 h, the solution was cooled to room 
temperature diluted with 113 mL of water. The resulting solution was extracted with Et2O (3 x 100 
mL) and the combined organic layers were washed with a solution of brine (3 x 100 mL), dried 
over sodium sulfate, and filtered, and concentrated. Purification with flash column 
chromatography on silica gel using 100% hexanes as the eluent afforded the β-azide 2.16 (1.53 g, 
82%). m.p. = 56-59˚C; TLC Rƒ = 0.41 (hexanes); 1H NMR (400 MHz, CDCl3) δ 3.29-3.17 (m, 
1H), 1.97 (dt, J = 12.8, 3.3 Hz, 1H), 1.86-1.72 (m, 3H), 1.71-1.63 (m, 1H), 1.62-1.44 (m, 5H), 
1.37-1.23 (m, 9H), 1.18-1.04 (m, 6H), 1.03-0.94 (m, 4H) 0.93-0.88 (m, 4H), 0.88 (d, J = 1.7 Hz, 
3H), 0.86 (d, J = 1.7 Hz, 3H), 0.79 (s, 3H), 0.65 (s, 4H); Anal calcd for C27H47N3: C, 78.39; H, 
11.45; N, 10.16. Found: C, 78.75; H, 11.54; N, 10.28. 
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3-Amino-5-cholestane (2.17)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
To a solution of β-azide 2.16 (1.46 g, 3.57 mmol) in 18 mL of anhydrous THF was added 
triphenylphosphine (1.40 g, 5.35 mmol). The solution was heated to 50˚C with the addition of 
water (0.100 mL, 5.55 mmol) in excess and stirred overnight (approx. 17 h). The reaction mixture 
was concentrated, and the residue purified by silica gel column chromatography, initially using 
90:10 DCM:MeOH solution as the eluent, then 90:9:1 DCM: methanol: 40% aq. ammonium 
hydroxide as the eluent to produce the β-amine 2.17 (1.18 g, 85%) as a white solid. m.p. = 154 ˚C 
(dec.); TLC Rƒ = 0.33 (DCM:MeOH;NH4OH, 90:9:1); 1H NMR (400 MHz, CDCl3) δ 2.71-2.61 
(m, 2H), 1.96 (dt, J = 12.8, 3.4 Hz, 1H), 1.88-1.74 (m, 1H), 1.72-1.69 (m, 1H), 1.68-1.65 (m, 1H), 
1.64-1.59 (m, 5H), 1.57-1.40 (m, 4H), 1.39-1.30 (m, 4H), 1.29-1.16 (m, 5H), 1.14-1.04 (m, 6H), 
1.03-0.92 (m, 4H), 0.89 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 1.8 Hz, 3H), 0.85 (d, J = 1.6 Hz, 3H), 0.78 
(s, 3H), 0.65 (s, 3H). 
H2N
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3-Amino-5-cholestane hydrochloride (2.3)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
β-amine 2.17 (1.18 g, 3.04 mmol) was dissolved in 20 mL of Et2O and allowed to stir while dry 
HCl gas was purged into the reaction mixture by the reaction of concentrated sulfuric acid and 
sodium chloride. During this time a precipitate formed. After approx. 5 min the reaction mixture 
was filtered and the white precipitate was collected and dried under vacuum producing the β-amine 
hydrochloride salt 2.3 (1.08 g, 83%) as a white solid. m.p. = 228˚C (dec.); 1H NMR (400 MHz, 
CDCl3) δ 8.29 (bs, 3H), 3.12 (bs, 1H), 2.03-1.92 (m, 2H), 1.86-1.69 (m, 3H), 1.68-1.64 (m, 1H), 
1.63-1.59 (m, 2H), 1.58-1.41 (m, 4H), 1.40-1.27 (m, 6H), 1.26-1.21 (m, 3H), 1.20-1.05 (m, 6H), 
1.04-0.93 (m, 4H), 0.89 (d, J = 6.4 Hz, 3H), 0.86 (d, J = 1.8 Hz, 3H), 0.85 (d, J = 1.8 Hz, 3H), 0.82 
(s, 3H), 0.64 (s, 3H); Anal calcd for C27H50ClN: C, 76.46; H, 11.88; N, 3.30.  Found: C, 76.18; H, 
11.76; N, 3.63. 
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5a-androstane-3b-ol (2.19)14,33 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
KOH (5.79 g, 103.3 mmol) was added to 30 mL diethylene glycol and heated until dissolved with 
a heat gun. Once the solution of KOH in diethylene glycol cooled to rt epiandrosterone 2.18 (6.00 
g, 20.7 mmol) and hydrazine hydrate (4.05 mL, 82.6 mmol) were added. With a reflux condenser 
attached the solution was heated to 245˚C and stirred continuously for 24 h. The condenser was 
removed and a distillate column attached to distill off diethylene glycol. The reaction was then 
cooled to rt and 100 mL MTBE and 100 mL brine were added and the solution stirred overnight. 
The aqueous phase was extracted with MTBE (10 x 60 mL). The collected organic phase was 
washed with brine (5 x 60 mL), dried with sodium sulfate, and concentrated down to produce 2.19 
(5.49 g, 95%) as a white solid. m.p. 148.4-150.2˚C; TLC Rf = 0.40 (hexane:EtOAc, 7:3); 1H NMR 
(400 MHz, CDCl3) δ 3.62-3.59 (m, 1H), 1.82-1.76 (m, 1H), 1.70-1.67 (m, 2H), 1.67-1.62 (m, 1H), 
1.61-1.58 (m, 1H), 1.57-1.51 (m, 4H), 1.50-1.48 (m, 1H), 1.49-1.36 (m, 2H), 1.35-1.29 (m, 2H), 
1.28-1.284 (m, 4H), 1.17-1.13 (m, 1H), 1.12-1.02 (m, 2H), 1.01-0.96 (m, 1H), 0.95-0.84 (m, 2H), 
0.82 (s, 3H), 0.70 (s, 3H), 0.67-0.60 (m, 1H). 
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3-Iodo-5-androstane (2.20)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
To a solution of 5a-androstane-3b-ol 2.19 (5.50 g, 19.9 mmol) and triphenylphosphine (10.7 g, 
41.8 mmol) in 120 mL benzene was added a solution of DIAD (8.45 mL, 41.8 mmol) in 12 mL of 
benzene dropwise. The resulting yellow solution was stirred at room temperature for 15 min before 
a solution of iodomethane (2.60 mL, 41.8 mmol) in 12 mL of benzene was slowly added dropwise. 
The reaction mixture was allowed to stir continuously for approx. 6 h before addition of another 
equiv of triphenylphosphine, DIAD, and iodomethane. The reaction was allowed to stir overnight 
for approx. 24 h before it was concentrated under reduced pressure, and purified by 
chromatography on silica gel using 100% hexanes as the eluent to afford the α-iodide 2.20 (4.51 
g, 60%) as an off white solid. m.p. = ; TLC Rf = 0.73; 1H NMR (300 MHz, CDCl3) δ 4.94-4.91 
(m, 1H), 1.92 (dt, J = 15.4, 3.3 Hz, 1H), 1.77-1.65 (m, 5H), 1.64-1.54 (m, 1H), 1.53-1.51 (m, 2H), 
1.47 (t,  J = 2.2 Hz, 1H), 1.46-1.38 (m, 2H), 1.37-1.22 (m, 4H), 1.21-1.05 (m, 4H), 1.04-0.98 (m, 
1H), 0.97-0.87 (m, 2H), 0.86-0.84 (m, 1H), 0.79 (s, 3H), 0.69 (s, 3H). 
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3b-azido-5-androstane (2.21)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
To a solution of the 3β-iodo-5-androstane 2.20 (4.50 g, 11.6 mmol) in 290 mL DMF was added 
NaN3 (3.77 g, 58 mmol). The reaction mixture was heated to 90˚C and stirred overnight, with the 
addition of another 0.5 equiv of NaN3. The reaction was allowed to cool to room temperature and 
quenched with the addition of 80 mL water. The reaction was extracted with ethyl acetate (3 x 50 
mL). The combined organic extracts were then washed with water (3 x 50 mL) and brine (3 x 50 
mL), dried over sodium sulfate and concentrated. Purification using chromatography on silica gel 
using 3:1 hexanes:EtOAc as eluent gave 3α-azide 2.21 (2.66 g, 76%). m.p. = 124 (dec.); TLC Rf  
= 0.90; 1H NMR (400 MHz, CDCl3) δ 3.25 (m, 1H), 1.86-1.78 (m, 1H), 1.76-1.67 (m, 3H), 1.65-
1.61 (m, 1H), 1.60-1.54 (m, 2H), 1.53-1.51 (m, 1H), 1.50-1.38 (m, 3H), 1.37-1.33 (m, 1H), 1.32-
1.29 (m, 1H), 1.28-1.26 (m, 2H), 1.25-1.19 (m, 1H), 1.18-1.04 (m, 4H), 1.01-0.92 (m, 1H), 0.91-
0.84 (m, 2H), 0.81 (s, 3H), 0.70 (s, 3H), 0.69-0.63 (m, 1H). 
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3b-amino-5-androstane hydrochloride K118 (2.5)14 
Lit. Ref: Viernes, D. R., “Synthesis, design, and biological evaluation of inhibitors and activators 
of Src Homology 2 domain-containing inositol phosphatase (SHIP) and synthetic studies of 
apicularen A and maoecrystal V” Syracuse University Dissertations, Department of Chemistry 
2012. 
 
3b-azido-5-androstane 2.22 (2.31 g, 8.40 mmol) was dissolved in 15 mL Et2O and stirred at 
room temperature as dry HCl gas, generated from the reaction of concentrated sulfuric acid and 
sodium chloride, was purged into the reaction mixture. The resulting precipitate was collected by 
vacuum filtration, washed with ethyl ether, and dried under vacuum to produce the 3α-amino-5α-
androstan-17-ethyl-ether hydrochloride salt 2.5 (2.44 g, 93%) m.p. = 254˚C (dec.); 1H NMR (300 
MHz, CDCl3) δ 8.31 (bs, 3H), 3.14 (bs, 1H), 2.10 (d, 1H), 1.81-1.65 (m, 6H), 1.64-1.55 (m, 3H), 
1.50-1.35 (m, 2H), 1.34-1.20 (m, 4H), 1.19-1.01 (m, 5H), 1.00-0.87 (m, 3H), 0.83 (s, 3H), 0.68 
(s, 3H). 13C NMR (100 MHz, CDCl3) δ 54.5, 54.3, 51.3, 45.1, 40.8, 40.4, 38.8, 36.7, 35.8, 35.5, 
33.2, 32.2, 28.3, 26.9, 25.5, 21.1, 20.5, 17.6, 12.3. Anal calcd for C19H34ClN: C, 73.16; H, 10.99; 
N, 4.49.  Found: C, 73.37; H, 11.11; N, 4.15. 
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3-ol-5-androstan-17-one 3-methanesulfonate (2.23)40 
Lit. Ref: Wang, Y.;  Ji, S.;  Wei, K.; Lin, J., Epiandrosterone-derived prolinamide as an efficient 
asymmetric catalyst for Michael addition reactions of aldehydes to nitroalkenes. RSC Adv. 2014, 
4, 30850-30856. 
 
Et3N (4.80 mL, 34.4 mmol) was added to a cooled, 0˚C, solution of 3β-hydroxy-5α-androstan-17-
one 2.18 (5.00 g, 17.2 mmol) in 172 mL DCM. MsCl (1.60 mL, 20.7 mmol) was slowly added 
into the reaction mixture. After approximately 3 h the reaction was quenched with 172 mL of 
water. The reaction was extracted with DCM (3 x 100 mL), and the combined organic extracts 
washed with water (3 x 100 mL) and brine (3 x 100 mL), dried over sodium sulfate and 
concentrated. Purification through chromatography on silica gel using 100% hexanes as the eluent, 
provided 3β-mesylate 2.23 (5.78 g, 91%). m.p. = 155-157 ˚ C; TLC Rƒ = 0.67 (hexane:EtOAc, 1:1); 
1H NMR (300 MHz, CDCl3) δ 4.69-4.58 (m, 1H), 3.00 (s, 3H), 2.47 (dd, J = 19.2, 8.7 Hz, 1H), 
2.17-1.18 (m, 3H), 1.85-1.76 (m, 4H), 1.75-1.61 (m, 3H), 1.60-1.53 (m, 1H), 1.52-1.43 (m, 1H), 
1.41-1.34 (m, 2H), 1.33-1.16 (m, 4H), 1.14-1.02 (m, 1H), 1.01-0.90 (m, 1H), 0.85 (s, 6H), 0.79-
0.65 (m, 1H). 
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3-azido-5-androstan-17-one (2.24)40 
Lit. Ref: Wang, Y.;  Ji, S.;  Wei, K.; Lin, J., Epiandrosterone-derived prolinamide as an efficient 
asymmetric catalyst for Michael addition reactions of aldehydes to nitroalkenes. RSC Adv. 2014, 
4, 30850-30856. 
 
To a solution of the 3β-mesylate 2.23 (5.78 g, 15.7 mmol) in 50 mL DMF was added NaN3 (2.04 
g, 31.4 mmol). The reaction mixture was heated to 90˚C and stirred overnight, with the addition 
of another 0.5 equiv of NaN3. The reaction was allowed to cool to room temperature and quenched 
with the addition of 80 mL water. The reaction was extracted with ethyl acetate (3 x 50 mL). The 
combined organic extracts were then washed with water (3 x 50 mL) and brine (3 x 50 mL), dried 
over sodium sulfate and concentrated. Purification using chromatography on silica gel using 3:1 
hexanes:EtOAc as eluent gave 3α-azide 2.24 (4.35 g, 88%). m.p. = 110-113˚C; TLC Rƒ = 0.66 
(hexane:EtOAc, 3:1); 1H NMR (400 MHz, CDCl3) δ 3.88 (t, J = 2.8 Hz, 1H), 2.44 (dd, J = 19.2, 
8.9 Hz, 1H), 2.13-2.02 (m, 1H), 1.97-1.89 (m, 1H), 1.83-1.77 (m, 2H), 1.74-1.69 (m, 1H), 1.68-
1.64 (m, 1H), 1.60-1.56 (m, 1H), 1.55-1.51 (m, 2H), 1.50-1.47 (m, 2H), 1.46-1.39 (m, 2H), 1.34-
1.25 (m, 4H), 1.24-1.16  (m, 3H), 1.02 (qd, J = 12.5, 4.8 Hz, 1H), 0.87 (s, 3H), 0.81 (s, 3H). 
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3-azido-5-androstan-17-ol (2.25)41 
Lit. Ref.: Amiranashvili, L. Sh.; Sladkov, V. I.; Levina, I. I.; Men'shova, N. I.; Suvorov, N. N. J. 
Org. Chem. USSR. 1990, 26, 1629-1632. 
 
A suspension of 3α-azide 2.24 (4.35 g, 13.8 mmol) in 138 mL methanol was cooled to 0˚C and 
NaBH4 (0.310 g, 8.27 mmol) was added. After approximately 4 h, the reaction was quenched with 
the addition of 27 mL 1M HCl and 137 mL NH4Cl. The methanol was removed in vacuo, and the 
resulting suspension extracted with ethyl acetate (3 x 100 mL). The combined organic extracts 
were washed with water (2 x 100 mL) and brine (3 x 100 mL), dried over sodium sulfate and 
concentrated down. After purification using chromatography on silica gel with 3:1 hexanes:EtOAc 
as the eluent  provided 3α-azido-5α-androstan-17-ol 2.25 (3.39 g, 77%) as a white solid. m.p. = 
134-137˚C; TLC Rƒ = 0.43 (hexane:EtOAc, 3:1); 1H NMR (400 MHz, CDCl3) δ 3.88 (t, J = 2.8 
Hz, 1H), 3.63 (t, J = 8.44 Hz, 1H), 2.21-2.09 (m, 1H), 1.79 (dt, J =12.4, 2.9 Hz, 1H), 1.74-1.60 
(m, 3H), 1.59-1.46 (m, 4H), 1.45-1.33 (m, 5H), 1.30-1.24 (m, 2H), 1.23-1.21 (m, 4H), 1.04 (td, J 
= 12.6, 4.0 Hz, 1H), 0.99-0.93 (m, 1H), 0.92-0.89 (m, 1H), 0.80 (s, 3H), 0.73 (s, 4H); 13C NMR 
(100 MHz, CDCl3) δ 81.9, 58.2, 54.3, 51.1, 43.0, 40.2, 36.7, 36.0, 35.5, 32.9, 32.6, 31.5, 30.5, 
28.2, 25.6, 23.4, 20.4, 11.6, 11.2.  
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3-azido-5-androstan-17-methyl-ether (2.26) 
3α-azido-5α-androstan-17-ol 2.25 (0.546 g, 1.72 mmol) was dissolved in 4 mL DMF.  NaH (0.248 
g, 10.32 mmol) was then added. After 1 h iodomethane (0.960 mL, 15.48 mmol) was added to the 
reaction mixture and then stirred overnight (approx. 18 h). Addition of 16 mL 1 M HCl and 16 mL 
DCM was then followed by separation of the organic layer. The aqueous phase was extracted using 
DCM (3 x 16 mL), the organic extracts combined, washed with water (3 x 15 mL) and brine (3 x 
15 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column 
chromatography on silica gel using 15% ethyl acetate:85% hexanes as the eluent to produce 3α-
azido-5α-androstan-17-methyl-ether 2.26 (0.305 g, 54%). m.p. = 103-109 ˚C; TLC Rƒ = 0.78 
(hexane:EtOAc, 3:1); IR (KBr) 2933 2089, 1687, 1451, 1360, 1269, 1100, 993, 663 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 3.88 (t, J = 2.8 Hz, 1H), 3.45 (s, 3H), 3.22 (t, J = 8.4 Hz, 1H), 2.05-1.95 (m, 
1H), 1.90 (dt, J = 11.6, 2.7 Hz, 1H), 1.75-1.63 (m, 3H), 1.62-1.33 (m, 8H) 1.32-1.09 (m, 7H), 1.02-
0.84 (m, 2H), 0.77 (s, 3H), 0.73 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 90.8, 58.2, 57.9, 54.3, 
51.3, 43.0, 40.1, 38.1, 36.0, 35.3, 32.9, 32.6, 31.5, 28.2, 27.7, 25.6, 23.4, 20.5, 11.6, 11.5; Anal 
calcd for C20H33N3O: C, 72.46; H, 10.03; N, 12.68.  Found: C, 72.82; H, 9.63; N, 12.28. 
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3-amino-5-androstan-17-methyl-ether (2.29) 
A solution of 3α-azido-5α-androstan-17-methyl-ether 2.26 (0.305 g, 0.920 mmol) was dissolved 
in 4.6 mL of anhydrous THF and triphenylphosphine (0.362 g, 1.38 mmol) was added. Water 
(0.100 mL, 5.55 mmol) was then added and the reaction mixture was warmed to 50 ˚C. After 
approx. 4 h the reaction was concentrated and the residue purified by column chromatography on 
silica gel initially using 90:10 DCM:MeOH solution as the eluent followed by a solution of 90:9:1 
DCM:MeOH:NH4OH to produce the white solid 3α-amino-5α-androstan-17-methyl-ether 2.29 
(0.251 g, 89%). m.p. = 105-107˚C; TLC Rƒ = 0.24 (DCM:MeOH:NH4OH, 90:9:1); IR (KBr) 3449 
3367, 3300, 2969, 2914, 2870, 2848, 2821, 1604, 1458, 1385, 1098, 890 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 3.35 (s, 3H), 3.27 (bs, 1H), 3.22 (t, J = 8.4 Hz, 1H) 2.94 (bs, 2H), 2.05-1.95 (m, 1H), 
1.90 (dt, J = 11.6, 2.6 Hz, 1H), 1.75 (tt, J = 14.2, 4.2 Hz, 1H), 1.69-1.62 (m, 1H), 1.61-1.33 (m, 
9H) 1.32-1.09 (m, 7H), 1.04-0.85 (m, 2H), 0.77 (s, 3H), 0.73 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 90.9, 57.8, 54.4, 51.3, 46.1, 42.9, 39.1, 38.1, 36.4, 35.4, 35.3, 32.1, 31.6, 28.6, 28.3, 27.7, 23.3, 
20.5, 11.7, 11.4; Anal calcd for C20H35NO: C, 78.53; H, 11.56; N, 4.58.  Found: C, 78.65; H, 11.56; 
N, 4.57. 
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3-amino-5-androstan-17-methyl-ether hydrochloride (2.6) 
3α-amino-5α-androstan-17-methyl-ether 2.29 (0.251 g, 0.822 mmol) was suspended in 10 mL 
Et2O. Dry HCl gas, produced by the reaction of concentrated sulfuric acid and sodium chloride, 
was purged into the reaction mixture for approx. 5 min. A precipitate formed during the gas purge. 
The precipitate was collected by vacuum filtration and washed with ethyl ether and dried under 
vacuum to produce the 3α-amino-5α-androstan-17-methyl-ether hydrochloride salt 2.6 (0.203 g, 
72%) as a white solid. m.p. = 254˚C (dec.); IR (KBr) 3460, 2928, 2017, 1604, 1503, 1458, 1382, 
1109, 675 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.03 (bs, 3H), 3.37 (s, 3H), 3.29-3.14 (m, 4H), 
2.03-1.89 (m, 1H), 1.84 (d, J = 11.2 Hz, 1H), 1.78-1.67 (m, 1H), 1.66-1.59 (m, 2H), 1.58-1.43 (m, 
4H), 1.42-1.27 (m, 4H), 1.26-1.03 (m, 5H), 1.02-0.89 (m, 1H) 0.88-0.79 (m, 1H), 0.77 (s, 3H), 
0.68 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 90.3, 57.5, 53.6, 51.3, 46.7, 43.0, 38.4, 38.0, 36.1, 
35.2, 31.5, 31.2, 30.9, 28.1, 27.6, 24.3, 23.4, 20.4, 12.1, 11.5; Anal calcd for C20H36ClNO: C, 
70.25; H, 10.61; N, 4.10.  Found: C, 69.95; H, 10.56; N, 4.03. 
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3-azido-5-androstan-17-ethyl-ether (2.27) 
A solution of 3α-azido-5α-androstan-17-ol 2.25 (0.750 g, 2.36 mmol) was dissolved in 4 mL DMF 
and NaH (0.340 g, 14.2 mmol) was added. The reaction mixture was stirred for 1 h, after which 
ethyl bromide (1.58 mL, 21.3 mmol) was added. After approximately 14 h 15 mL of 1M aq. HCl 
solution was added. The reaction mixture was then extracted with DCM (3 x 10 mL). The 
combined organic extracts were washed with water (3 x 10 mL) and brine (3 x 10 mL), dried with 
sodium sulfate and concentrated. Purification of the residue by column chromatography on silica 
gel using 80% hexanes:20% ethyl acetate produced the product 3α-azido-5α-androstan-17-ethyl-
ether 2.27 (0.651 g, 80%). m.p. = 91-93˚C; TLC Rƒ = 0.82 (hexane:EtOAc, 3:1); IR (KBr) 2917, 
2874, 2852, 2077, 1442, 1405, 1379, 1263, 1123, 973 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.88 (t, 
J = 2.8 Hz, 1H), 3.59-3.43 (m, 2H), 3.30 (t, J = 8.3 Hz, 1H), 2.04-1.94 (m, 1H), 1.88 (dt, J = 11.7, 
2.9 Hz, 1H), 1.75-1.67 (m, 2H), 1.66-1.63 (m,1H), 1.55-1.47 (m, 4H), 1.46-1.29 (m, 4H), 1.28-
1.12 (m, 9H), 1.00-0.83 (m, 2H), 0.79 (s, 3H), 0.77-0.71 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 
89.0, 65.4, 58.2, 54.4, 51.4, 43.0, 40.1, 38.2, 35.9, 35.3, 32.9, 32.5, 31.5, 28.2, 28.2, 25.6, 23.3, 
20.5, 15.8, 11.7, 11.6; Anal calcd for C21H35N3O: C, 73.00; H, 10.21; N, 12.16.  Found: C, 72.77; 
H, 10.42; N, 11.88.  
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3-amino-5-androstan-17-ethyl-ether (2.30) 
3α-azido-5α-androstan-17-ethyl-ether 2.27 (0.600 g, 1.73 mmol) was dissolved in 9 mL of 
anhydrous THF and heated to 50 ˚C.  Triphenylphosphine (0.911 g, 3.47 mmol) and water (0.100 
mL, 5.55 mmol) were then added and the reaction mixture was stirred for approximately 4 h. The 
solvent was then removed in vacuo and the residue purified by column chromatography on silica 
gel using 90:10 DCM:MeOH initially as the eluent, followed by a 90:9:1 solution of DCM:MeOH: 
40% aq. ammonium hydroxide to produce the product 3α-amino-5α-androstan-17-ethyl-ether 2.30 
(0.420 g, 76%) as a white solid. m.p. = 88-92˚C; TLC Rƒ = 0.31 (DCM:MeOH:NH4OH, 90:9:1); 
1H NMR (400 MHz, CDCl3) δ 3.59-3.42 (m, 2H), 3.30 (t, J = 8.3 Hz, 1H), 3.22 (bs, 1H), 2.32 (bs, 
2H), 2.05-1.94 (m, 1H), 1.89 (dt, J = 11.8, 2.8 Hz, 1H), 1.81-1.62 (m, 2H), 1.61-1.32 (m, 8H) 1.32-
1.10 (m, 10H), 1.01-0.83 (m, 2H), 0.79 (s, 3H), 0.75 (s, 4H); 13C NMR (75 MHz, CDCl3) δ 89.0, 
65.3, 62.6, 54.5, 51.4, 46.0, 43.0, 39.2, 38.2, 36.4, 35.4, 32.1, 31.6, 28.7, 28.6, 28.3, 23.3, 20.5, 
15.7, 11.7, 11.3; Anal calcd for C21H37NO: C, 78.94; H, 11.67; N, 4.38.  Found: C, 78.75; H, 11.67; 
N, 4.58. 
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3-amino-5-androstan-17-ethyl-ether hydrochloride (2.7) 
3α-amino-5α-androstan-17-ethyl-ether 2.30 (0.420 g, 0.131 mmol) was dissolved in 10 mL Et2O 
and stirred at room temperature as dry HCl gas, generated from the reaction of concentrated 
sulfuric acid and sodium chloride, was purged into the reaction mixture. The resulting precipitate 
was collected by vacuum filtration, washed with ethyl ether, and dried under vacuum to produce 
the 3α-amino-5α-androstan-17-ethyl-ether hydrochloride salt 2.7 (0.385 g, 82%). m.p. = 241˚C 
(dec.); TLC Rƒ = 0.21 (DCM:MeOH:NH4OH, 90:9:1); IR (KBr) 3329, 2945, 2032, 1618, 1494, 
1458, 1445, 1380, 1110, 674 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 7.87 (bs, 3H), 3.47-3.36 (m, 
4H), 2.03-1.28 (m, 15H), 1.22-1.013 (m, 4H), 1.07 (t, J = 6.9 Hz, 4H), 1.01-0.83 (m, 2H), 0.76 (s, 
3H), 0.68 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 89.5, 79.8, 64.9, 53.7, 51.3, 46.8, 43.1, 38.6, 
38.1, 36.1, 35.3, 31.6, 31.2, 31.0, 28.2, 24.3, 23.4, 20.4, 16.2, 12.2, 11.5. Anal calcd for 
C21H28ClNO: C, 70.85; H, 10.76; N, 3.93.  Found: C, 70.84; H, 10.4; N, 3.70. 
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3-azido-5-androstan-17-n-butyl-ether (2.28) 
NaH (0.378 g, 15.7 mmol) was added to a solution of 3α-azido-5α-androstan-17-ol 2.25 (0.500 g, 
1.57 mmol) in 3.6 mL DMF. After 1 h n-butyl bromide (1.70 mL, 15.7 mmol) and tetra-butyl-
ammonium iodide (0.02 g) were added, and the reaction mixture was stirred. After approx. 5 h 
addition of another equiv of n-butyl bromide was added and the reaction was stirred overnight for 
approx. 23 h. 15 mL of 1M HCl was added slowly followed by 15 mL ethyl acetate, and the 
aqueous phase separated. The organic phase was washed with brine (3 x 15 mL), dried with sodium 
sulfate, concentrated down, and ran purified through column chromatography using 100% hexanes 
as the eluent to produce 3α-azido-5α-androstan-17-n-butyl-ether 2.28 (0.414 g, 70%). m.p. = 75-
78˚C; TLC Rƒ = 0.76 (hexane:EtOAc, 3:1); IR (KBr) 2925 2845, 2112, 2086, 1458, 1268, 1112, 
978, 620 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.88 (t, J = 2.8 Hz, 1H), 3.49-3.36 (m, 2H), 3.28 (t, 
J = 8.2 Hz, 1H), 2.03-1.92 (m, 1H), 1.88 (dt, J = 11.9, 3.0 Hz, 1H), 1.74-1.61 (m, 3H), 1.73-1.46 
(m, 6H), 1.45-1.29 (m, 6H), 1.28-1.08 (m, 6H), 0.99-0.83 (m, 5H), 0.79 (s, 3H), 0.74 (s, 4H); 13C 
NMR (100 MHz, CDCl3) δ 89.1, 69.9, 58.2, 54.4, 51.3, 43.1, 40.1, 38.1, 35.9, 35.3, 32.9, 32.6, 
32.4, 31.5, 28.2, 28.2, 25.7, 23.3, 20.5, 19.4, 13.9, 11.7, 11.6; Anal calcd for C23H39N3O: C, 73.95; 
H, 10.52; N, 11.25.  Found: C, 73.83; H, 10.63; N, 10.79.  
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3-amino-5-androstan-17-n-butly-ether (2.31) 
3α-azido-5α-androstan-17-n-butyl-ether 2.28 (0.368 g, 0.985 mmol) was dissolved in 5 mL 
anhydrous THF. Triphenylphosphine (0.388 g, 1.48 mmol) was added and the reaction mixture 
was heated to 50 ˚C. Water (0.100 mL, 5.55 mmol) was then added and the reaction stirred for 5 
h. The reaction was allowed to cool to room temp and the solvent was removed in vacuo. 
Purification by column chromatography on silica gel using 90:10 DCM:MeOH as the initial eluent, 
followed by a 90:9:1 solution of DCM:MeOH:NH4OH produced 3α-amino-5α-androstan-17-n-
butyl-ether 2.31 (0.266 g, 78%) as a white solid. m.p. = 132 (dec.); TLC Rƒ = 0.27 
(DCM:MeOH:NH4OH, 90:9:1); 1H NMR (400 MHz, CDCl3) δ 3.48-3.37 (m, 2H), 3.34 (bs, 1H), 
3.27 (t, J = 8.6 Hz, 1H), 2.79 (bs, 2H), 2.05-1.92 (m, 1H), 1.87 (dt, J = 11.9, 2.9 Hz, 1H), 1.78 (tt, 
J = 14.4, 4.0 Hz, 1H), 1.70-1.61 (m, 1H) 1.60-1.57 (m, 1H) 1.56-1.44 (m, 7H), 1.43-1.28 (m, 6H), 
1.27-1.05 (m, 5H) 1.03-0.93 (m, 1H), 0.91 (t, J = 7.4 Hz, 4H), 0.79 (s, 4H), 0.74 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 89.1, 69.9, 54.2, 51,3, 46.5, 43.1, 39.1, 38.1, 36.3, 35.4, 34.4, 32.4, 31.9, 
31.6, 28.5, 28.2, 27.4, 23.4, 20.5, 19.5, 14.0, 11.7, 11.4; Anal calcd for C23H41NO: C, 79.48; H, 
11.89; N, 4.03.  Found: C, 79.11; H, 11.98; N, 4.00.  
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3-amino-5-androstan-17-n-butyl-ether hydrochloride (2.8) 
3α-amino-5α-androstan-17-n-butyl-ether 2.31 (0.221 g, 0.636 mmol) was suspended in 10 mL 
Et2O and stirred at room temperature as dry HCl gas, produced from the reaction of concentrated 
sulfuric acid and sodium chloride, was purged into the reaction mixture for approximately 5 min. 
The resulting precipitate was collected by vacuum filtration, washed with ethyl ether and dried 
under vacuum to produce the 3α-amino-5α-androstan-17-n-butyl-ether hydrochloride salt 2.8 
(0.176 g, 72%) as a white solid. m.p. = 186 °C (dec.); TLC Rƒ = 0.27 (DCM:MeOH: 40% aq. 
ammonium hydroxide, 90:9:1); IR (KBr) 3335, 2944, 2566, 2032, 1619, 1495, 1458, 1445, 1263, 
1218, 1125 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 7.98 (bs, 3H), 3.48-3.33 (m, 3H), 3.26 (t, J = 
8.2 Hz, 1H), 2.01-1.89 (m, 1H), 1.81 (d, J = 11.4 Hz, 1H), 1.71 (d, J =14.1 Hz, 1H), 1.67-1.57 (m, 
2H), 1.56-1.39 (m, 8H), 1.38-1.27 (m, 5H), 1.26-1.09 (m, 5H), 0.91-0.88 (m, 2H), 0.87 (t, J = 7.6, 
3H), 0.80-0.71 (m, 4H), 0.69 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 88.6, 69.3, 53.7, 51.3,46.7, 
43.0, 38.5, 38.0, 35.9, 35.2, 32.3, 31.5, 31.2, 30.9, 28.1, 28.1, 24.3, 23.4, 20.4, 19.4, 14.2, 12.1, 
11.5; Anal calcd for C23H42ClNO: C, 71.93; H, 11.02; N, 3.65.  Found: C, 71.57; H, 10.83; N, 
3.35. 
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3-amino-5-androstan-17-undecyn-ether hydrochloride (2.10) 
3α-amino-5α-androstan-17-undecyn-ether 2.35 (0.41 g, 0.930 mmol) was suspended in 10 mL 
Et2O and stirred at room temperature as dry HCl gas, produced from the reaction of concentrated 
sulfuric acid and sodium chloride, was purged into the reaction mixture for approximately 5 min. 
The resulting precipitate was collected by vacuum filtration, washed with ethyl ether and dried 
under vacuum to produce the 3α-amino-5α-androstan-17-undecyn-ether hydrochloride salt 2.10 
(1.57 g, 35%) as a white solid. m.p. = 243°C (dec.); TLC Rƒ = 0.27 (DCM:MeOH: 40% aq. 
ammonium hydroxide, 90:9:1); 1H NMR (400 MHz, CDCl3) δ 8.42 (bs, 3H), 3.61 (bs, 1H), 3.48-
3.32 (m, 2H), 3.24 (t, J = 8.2 Hz, 1H), 2.18 (td, J = 10.3, 5.8 Hz, 2H), 1.93 (t, J =2.6 Hz, 2H), 1.92-
1.80 (m, 3H), 1.79-1.60 (m, 4H), 1.52-1.43 (m, 7H), 1.42-1.32 (m, 4H), 1.31-1.09 (m, 13H), 1.08-
0.87 (m, 4H), 0.79 (s, 3H), 0.73  (s, 3H); 13C NMR (100 MHz, CDCl3) δ 89.2, 84.8, 77.2, 70.3, 
68.1, 53.0, 50.9, 47.7, 43.1, 38.7, 37.9, 36.1, 35.3, 31.4, 31.3, 30.2, 29.5, 29.4, 29.1, 28.8, 28.5, 
28.2, 26.3, 24.7, 23.3, 20.5, 18.4, 11.7, 11.23, 1.02; Anal calcd for C30H52ClNO: C, 75.35; H, 
10.96; N, 2.93.  Found: C, 75.3; H, 10.9; N, 2.62. 
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Abstract 
Increasing the phosphatase activity of SHIP1 through activation with an allosteric agonist 
may reduce PI3K signaling. SHIP1 is allosterically activated as its own product, PI(3,4)P2, binds 
to the enzyme and increases activity. This upregulation of SHIP1 further increases the rate of 
hydrolysis of PI(3,4,5)P3, reducing the activation of protein kinase AKT from binding of 
PI(3,4,5)P3 but promoting signaling from the interaction of PI(3,4)P2 with AKT. With this 
understanding the potential for small molecules to allosterically bind and accelerate SHIP1 
phosphatase activity will further drive the hydrolysis of PI(3,4,5)P3. The complicated nature of 
these interactions demonstrates the need for small molecule SHIP1 agonists to investigate the role 
of SHIP1 in PI3K signaling. Several small molecule SHIP1 agonists have been reported in the 
literature. These studies culminated in the identification by Aquinox Pharmaceuticals of AQX-
1125, which recently underwent clinical evaluation for interstitial cystitis / bladder pain syndrome. 
To facilitate our own studies on SHIP1 signaling, a new synthetic route to the SHIP1 agonist AQX-
1125 has been developed. This route is significantly more rapid than the previously published route 
(17 steps), requiring only 12 steps from the commercially available dehydroepiandrosterone.  
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3.1 Introduction 
Investigations into the inhibition of PI3K have been pursued with some isoform-specific 
inhibitors being developed and proceeding through clinical trials.1-4 One difficulty in targeting 
PI3K is with the off-target effects caused by the inhibition of an undesired PI3K isoform. However, 
regulation of the intercellular signaling responses through the PI3K pathway can also be achieved 
by targeting SHIP, the negative regulator of PI(3,4,5)P3, and this enzyme only exists in two 
isoforms, SHIP1 and SHIP2. Expressed primarily in hematopoietic cells,5 SHIP1 plays a key role 
in blood and bone marrow cellular physiology, whereas the other paralog SHIP2 is utilized for a 
similar role in other cells.6-10 Modulating SHIP could allow for the development of alternative 
therapeutic treatments for multiple human disorders11 such as cancer,3,12-16 autoimmune 
disease,13,14 cardiovascular disease,13,14 obesity,17,18 and chronic inflammatory conditions.14,15,19  
Interest in modulation of SHIP to influence the PI3K signaling pathway led Andersen, 
Krystal and Mui to screen a library consisting of roughly 2000 marine invertebrate extracts. This 
screening led to the identification of the meroterpenoid pelorol 3.1 from the Papua New Guinea 
sponge Dactylospongia elegans as a SHIP1 agonist (Figure 3.1). This molecule was shown to act 
as a selective SHIP1 agonist in a chromogenic enzyme assay.20 Although pelorol was 
independently isolated and identified by Golcik et al.21 and Kwak et al.,22 these studies just 
described the isolation and characterization of pelorol, and did not mention the activation of SHIP1 
enzymatic activity.20 Further evaluation of the agonist activity demonstrated by pelorol towards 
SHIP1 was facilitated by a total synthesis of the molecule which was developed by Yang and co-
workers. This synthesis utilized the commercially available and inexpensive terpenoid (+)-
sclareolide 3.2 as the starting material.14,15,20,23   
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Figure 3.1: Structure of Pelorol 3.1 Synthesized from (+)-Sclareolide 3.2 
 
 
Evaluation of synthetic pelorol 3.1, the intermediates from the total synthesis as well as a 
number of pelorol analogs led to the identification of AQX-016A 3.3 as an even more potent 
SHIP1 agonist. This molecule was reported to be approximately three times more active than 
pelorol when tested against SHIP1 at the same concentration. A number of further studies were 
then performed using the more potent agonist AXQ-016A 3.3 (Figure 3.2).14,20,23,24 To address 
selectivity concerns on other inositol phosphatases, AQX-016A 3.3 was tested against the other 
paralog of SHIP, SHIP2. Using a number of in vitro enzyme assays, the phosphatase activity of 
SHIP1 showed an increase with increasing concentration of AQX-016A 3.3 but no increase was 
observed for SHIP2 phosphatase activity.14,20 Therefore it was concluded that these agonists exert 
their biological effects through interactions solely with SHIP1. 
 
Figure 3.2: Structure of AQX-016A 3.3 (A) Activity Towards SHIP Enzyme (B) Selectivity for 
SHIP1 vs SHIP2 20 
 
 
H
HO OH
CO2Me
H
pelorol (3.1)
O
H
H
sclareolide (3.2)
O
9 steps, 22% yield
H
OH
H
HO
AQX-016A (3.3)
A B 
 82 
Furthermore, analysis of the ability of AQX-016A 3.3 to upregulate SHIP1 activity in the 
PI3K signaling pathway in cells was investigated. Prior experiments demonstrated that 
macrophages stimulated with lipopolysaccharides (LPS) activate PI3K signaling and generate a 3- 
to 5-fold increase in PI(3,4,5)P3, which drives an inflammatory response.20 Upon treatment with 
AQX-016A 3.3, PI(3,4,5)P3 levels in LPS treated macrophages decreased, as was expected since 
increasing SHIP1 activity will convert the PI(3,4,5)P3 to the hydrolyzed product PI(3,4)P2 (Figure 
3.3).20 As a positive control, LPS stimulated macrophages were also treated with a known PI3K 
inhibitor LY294002.25 The PI3K inhibitor showed a similar result with no PI(3,4,5)P3 observed, 
signifying that both LY294002 and AQX-016A 3.3 are targeting the PI3K signaling pathway.20 
Additional support that AQX-016A 3.3 was targeting SHIP1 was obtained from measuring the 
amount of PI(3,4)P2 after treatment of the cells with LY294002 and AQX-016A 3.3. As a 5' 
inositol phosphatase, treatment of the cells with a SHIP1 agonist should lead to a significant 
increase in the amount of PI(3,4)P2 in the cells. The PI3K inhibitor LY294002 should not show 
this increase, since it is stopping formation of the PI(3,4,5)P3 by halting addition of the 3' phosphate 
to the inositol via inhibition of the parent kinase PI3K. These expectations are consistent with the 
results shown in Figure 3.3B, where treatment with AQX-016A 3.3 provides significantly more 
PI(3,4)P2 than treatment with LY294002, but both lead to a drop in PI(3,4,5)P3.  
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Figure 3.3: PI(3,4,5)P3  (A) vs PI(3,4)P2 (B) Concentrations in AQX-016A 3.3 Treated 
Macrophages Stimulated with LPS20 
 
 Another recognizable response to LPS stimulated macrophages is an increase in PI3K 
induced production of proinflammatory cytokines such as TNFα.26 Increased cell concentrations 
of PI(3,4,5)P3  activate an inflammatory response, and therefore an LPS challenge increases TNFa 
production and leads to inflammation. Treatment with a SHIP1 agonist should drive the hydrolysis 
of the 5' phosphate from the inositol and lower the amount of PI(3,4,5)P3 present, leading to less 
TNFa and acting as an anti-inflammatory agent. This reduction in TNFα production can easily be 
measured with an antibody using a commercially available ELISA kit, providing an assay for new 
small molecules with anti-inflammatory properties. Evaluation of AQX-016A 3.3 in this assay 
demonstrated a 30% decrease in TNFα at 3µM and 50% decrease at 15 µM.(Figure 3.4).20 This 
study was performed using LPS challenged bone marrow-derived macrophages (BMDM) that 
express SHIP1 (SHIP+/+). To further validate the role of AQX-016A 3.3 in reducing TNFα by 
activating SHIP1, BMDM that were modified to be SHIP1 deficient (SHIP-/-) gave no observed 
decrease in TNFα,  signifying that AQX-016A 3.3 was specifically modulating SHIP1 activity in 
these systems.20 A comparison study using LY294002 gave a similar result showing a decrease in 
A B 
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TNFα (40% at 15 µM) due to a lack of PI(3,4,5)P3. Again, this was due to a lack of PI(3,4,5)P3 as 
the PI3K kinase enzyme being inhibited, so the 3'-phosphate could not be installed. Using 
LY294002 the decrease in TNFa was observed in both SHIP+/+ and SHIP-/- BMDM, demonstrating 
that the PI3K inhibitor was  active through a different mechanism than AQX-016A 3.3 .20  
 
Figure 3.4: Reduction of TNFα in BMDM Treated with AQX-016A 3.320 
 
 
 
 
 
 
 
 
While the in vitro studies were quite promising, AQX-MN100 and the other pelorol 
analogs had yet to show if they were active and robust enough to activate SHIP1 in a whole animal. 
In vivo studies were then undertaken in mice. These studies showed that AQX-016A 3.3 was able 
to reduce an inflammatory response induced from LPS injections.20 Mice pretreated with AQX-
016A 3.3 orally 30 minutes prior to the injection showed a decreased amount of serum TNFα levels 
(Figure 3.5).20 This reduced level of TNFα was comparable to mice treated with dexamethasone, 
a known macrophage inhibitor.20 These studies showed that AQX-016A could function as a SHIP1 
agonist in an animal and, importantly, also demonstrated that the small molecule was active 
through oral dosing. 
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Figure 3.5: In vivo Reduction of Serum TNFα of Mice Treated with SHIP1 Agonist AQX-016A 
3.3 Comparable to Mice Treated with Macrophage Inhibitor Dexamethasone 20 
 
 
Although the molecule was demonstrated to be an orally bioavailable, potent and selective 
agonist for SHIP1, the catechol functionality in AQX-016A 3.3 gave rise to concerns over toxicity 
and potential side effects. Catechols are well known to bind metals and/or are easily oxidized to 
orthoquinones under physiological conditions by cytochrome P450 enzymes, which are near 
ubiquitous. These orthoquinones can cause covalent modifications to proteins and DNA through 
Michael reactions.14,20 To overcome these issues, further structure activity studies were performed 
on the pelorol system. Eventually the phenol AQX-MN100 3.4 was developed. This molecule was 
similar to AQX-016A but lacked the hydroxyl functionality at C17. AQX-MN100 showed 
equivalent selectivity as AQX-016A 3.3 (Figure 3.6)14,20,21 for SHIP1, and actually appeared to be 
a slightly more potent agonist. 
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Figure 3.6: Structure of AQX-MN100 3.4 and (A) Comparison of SHIP1 Activity to AQX-016A 3.3 
(B) TNFα Reduction with AQX-MN100 3.4 (C) Agonist Activity Occurs Through Allosteric 
Activation at the C2 Domain of SHIP120 
  
 
 
 
 
 
 
 
 
 
 
Further studies with AQX-MN100 3.4 as a SHIP1 agonist revealed that the allosteric 
recognition site (where the agonist binds to the enzyme to increase activity) is localized on the C2-
domian of the protein (Figure 3.7).14,20 To determine the location of the allosteric agonist binding 
site, Anderson and co-workers analyzed SHIP1 phosphatase activity towards the wild-type enzyme 
or a C2-domain deleted SHIP1 mutant. Treatment with AQX-MN100 3.4 led to increased activity 
for the wild-type SHIP1 enzyme, but no increase was demonstrated for the C2-domain deleted 
mutant protein.20 Interestingly the product of SHIP1 hydrolysis, PI(3,4)P2, also was shown to cause 
an increase in phosphatase activity. This demonstrates that the SHIP1 product is likely the 
endogenous ligand for the allosteric site on the C2 domain, with some of the product of the 
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hydrolysis of PI(3,4,5)P3 binding to the enzyme and increasing the rate of hydrolysis of more 
PI(3,4,5)P3.20 While these pelorol derivatives were the first small molecules which were shown to 
be SHIP1 agonists, their development was eventually discontinued due to concerns about their 
pharmacodynamics, which appeared to be poor as the molecules are quite nonpolar. 
 
Figure 3.7: AQX-MN100 3.4 Increases SHIP1 Activity Allosterically Through the C2-Domain 
 
 
 
 
 
 
 
Continued efforts in developing new SHIP1 agonists by Aquinox Pharmaceuticals led to 
the undisclosed identification of AQX-MN115 3.5 and the seco-steroidal indene AQX-1125 3.6, 
potentially through a screen of indene analogs developed by Inflazyme Pharmaceuticals (Figure 
3.8).27 While AQX-MN115 3.5 showed an increase in SHIP1 activity by 77% at 300 µM, AQX-
1125 3.6 only showed a 20% increase at the same concentration.28 Although less potent, AQX-
1125 3.6 displays exceptional pharmacokinetics and was therefore advanced as the new lead 
compound. A patented 17 step synthesis of AQX-1125 3.6 was developed from commercially 
available dehydroepiandrosterone with an overall yield of 13%.29  
 
 88 
Figure 3.8: Structure of AQX-MN115 3.5 and AQX-1125 3.6 (Synthesized from 
Dehydroepiandrosterone 3.7) 
 
 
AQX-1125 3.6 showed no toxicity in a phase I clinical trial, and was quickly moved on to 
a phase II clinical trial to test for anti-asthmatic properties.28,30 AQX-1125 3.6 is the first SHIP1 
modulator to reach clinical trials. However, while the phase I trial demonstrated safety and did 
seem to show some efficacy, the later phase II trials did not show sufficient evidence of efficacy 
for treatment of COPD.31 The molecule is now being evaluated for a number of other inflammatory 
conditions. For example, AQX-1125 3.6 was recently evaluated in a phase III clinical trial for the 
treatment of bladder pain syndrome/interstitial cystitis (BPS/IC), a chronic inflammatory bladder 
disease.32 Again the molecule did not demonstrate efficacy in this clinical trial. The reason for the 
lack of efficacy in these clinical settings is currently unclear, but AQX-1125 3.6 has shown only a 
20% increase in SHIP1 activity at 300 µM and this may not be potent enough activity to show an 
anti-inflammatory effect at the organismal level. Aquinox appears to be continuing development 
of AQX-1125 3.6 and other SHIP1 agonists as anti-inflammatories. 
Initially, the Aquinox synthesis of AQX-1125 3.6 begins with the commercially available 
dehydroepiandrosterone 3.7 (Scheme 3.1). Using ethylene glycol and p-toluenesulfonic acid a 
ketal was installed from the C17 ketone leading to structure 3.8. Protection of the C3 hydroxy 
group as the tert-butyldimethylsilyl ether 3.9 was then executed with TBDMSCl and imidazole. 
This was followed by the allylic oxidation of alkene 3.10 with a ruthenium catalyst generating 
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ketone 3.10. While this oxidation is well precedented in the literature, it is known to proceed in 
moderate yield as there are many allylic positions in the molecule and the selectivity of this process 
is problematic. Reduction of enone 3.10 using Luche conditions33 leads to the allylic alcohol 
3.11.29  
 
Scheme 3.1: Aquinox Synthesis Formation of the Allylic Alcohol 3.11 
 
Hydroboration-oxidation of the allylic alcohol 3.11 then accessed the diol 3.12 (Scheme 
3.2). Deprotection of the C17 ketal and the TBDMS group was accomplished using 80% aq. acetic 
acid, which formed ketone 3.13. The diol was then protected as an acetonide  to provide the ketone 
3.14.29  
 
Scheme 3.2: Aquinox Synthesis Formation of the Acetonide 3.14 
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A Wittig reaction was then performed on the 3.14 carbonyl at C17 to generate the exocyclic 
olefin 3.15 (Scheme 3.3). The protection of the C3 alcohol as the acetate 3.16 was then 
accomplished with acetic anhydride and pyridine. This was followed by acid promoted hydrolysis 
of the acetonide, producing diol 3.17. Oxidative cleavage of the diol with sodium periodate opened 
the steroid B ring to provide dialdehyde 3.18.29  
 
Scheme 3.3: Aquinox Synthesis Formation of the Dialdehyde 3.18 
 
 
Dialdehyde 3.18 was then reduced using sodium borohydride to generate intermediate diol 
3.19. This diol was then selectively protected as the monoacetate 3.20 (Scheme 3.4). This 
monoprotection reaction was claimed to be selective, but no reasoning for this selectivity was 
given in the patent. The less reactive alcohol was then activated as the mesylate with 
methanesulfonyl chloride and triethylamine to provide mesylate 3.21. Displacement of the 
mesylate 3.21 was accomplished using sodium azide in DMF, providing the azide 3.22.29  
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Scheme 3.4: Aquinox Synthesis Formation of the Azide 3.22 
 
 
This azide 3.22 was then was reduced to the primary amine 3.23 with lithium aluminum 
hydride (Scheme 3.5). This reduction was also effective in removing the acetate from the C3 
alcohol. To complete the synthesis the acetate salt of the free amine 3.23 was formed generating 
AQX-1125 3.6.29,34  
 
Scheme 3.5: Aquinox Synthesis Formation of the AQX-1125 3.6 
 
 
Even though AQX-1125 3.6 has performed poorly in clinical trials, 28,30-32 it remains the 
only compound targeting SHIP1 to advance to the clinic. Given its ability to activate SHIP1 and 
its excellent pharmacodynamic properties, the molecule may still be useful as a reagent to probe 
the role of SHIP1 on signaling in the PI3K pathway, especially in murine settings. Given our own 
studies on the role of SHIP modulation in human disease,35-37 we undertook a synthesis of AQX-
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1125 3.6 to provide material for to further study the effects of upregulating SHIP1. Given the 
length of the synthesis developed by Aquinox, some effort was expended into developing a shorter 
synthesis of the molecule so that it could be produced more quickly and efficiently. 
 
3.2 Development of a New Synthetic Route to AQX-1125 
 A new synthetic route to the SHIP1 agonist AQX-1125 3.6 has been developed. Some 
initial studies on this route were performed previously by lab colleague Dr. Brian C. Duffy.34 This 
route is significantly more rapid than the previously published route, requiring only 12 steps from 
the commercially available dehydroepiandrosterone 3.7. Retrosynthetically the new route utilizes 
the lactone intermediate 3.25 which facilitates differentiation of the C6 and C7 positions (steroid 
numbering). This results in a completely regioselective synthesis of this complex molecule 
(Scheme 3.6). In addition, some intermediates and analogs have been prepared, providing evidence 
that the C17 alkene is not relevant for maintaining SHIP1 agonist activity in preliminary malachite 
green assays. 
 
Scheme 3.6: Proposed Retrosynthetic Analysis of AQX-1125 3.6 
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3.3 Results and Discussion 
The first three steps of the new synthesis of AQX-1125 follow from the literature. First the 
ketal 3.8 is produced using a catalytic amount of toluenesulfonic acid, ethylene glycol, and benzene 
at reflux using a Dean-Stark trap (Scheme 3.7) to remove water from the reaction mixture. The 
alcohol on the C3 position was then protected as the TBS ether 3.9. Both of these steps proceeded 
with good conversion. No purification was required over these first two steps, with the crude 
product being pure enough to go on to the next step. The allylic oxidation using a ruthenium 
catalyst was then performed on alkene 3.9 to generate the a,b-unsaturated ketone 3.10. The yield 
of this reaction is generally moderate due to the multiple allylic sites and harsh oxidation 
conditions producing a mixture of products.29,34,38,39 However, purification via recrystallization 
allowed for the product 3.10 to be easily separated from the byproducts produced in the 
reaction.29,38 This is convenient as ketone 3.10 can be isolated on large scale (3.41 g 3.10) from 
starting dehydroepiandrosterone 3.7 without chromatography.29,38 From here the synthetic route 
diverges from the Aquinox route. Using 10% palladium on carbon in ethyl acetate a hydrogenation 
of the unsaturated ketone 3.10 produced the favored trans-decalin 3.28. The delivery of the 
hydrogen from the bottom face of the steroid is consistent with the angular methyl groups blocking 
the top face of the molecule from attack. Similar stereochemistry has been generated by 
hydrogenation of C5-C6 alkenes is other steroid systems.39  
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Scheme 3.7: Synthesis of Ketone Intermediate 3.28 
 
 The ketone 3.28 was then transformed into the silyl enol ether 3.27 in good yields using 
tert-butyldimethylsilyl trifluoromethanesulfonate and triethylamine in dichloromethane (Scheme 
3.8). This reaction was selective for formation of the less highly substituted silyl enol ether, as is 
consistent with literature reports in similar systems.40 Purification by column chromatography is 
required to remove the byproducts produced during the silyl enol ether formation. Previous work 
attempted to oxidatively cleave the TBS enol ether through ozonolysis34 without purification, 
which led to issues with isolation and confirmation of the acid product 3.26. Therefore initially a 
synthetic alternative was investigated. Using the silyl enol ether 3.27, a Rubottom oxidation41 was 
performed using m-CPBA and NaHCO3 in DCM at 0˚C (Scheme 3.8) followed by deprotection 
using 10% aq. HCl 3.29. An oxidative cleavage with sodium periodate NaIO429 of 3.29 to generate 
the free acid/alcohol 3.30 system was found to show no reaction.  
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Scheme 3.8: Synthesis of Acid Intermediate 3.31 
 
 
  
 
 
 
 
With the alternative route being problematic, reevaluation of the ozonoylsis was attempted. 
The goal was to fully identify and confirm product formation by following the reaction as it 
progressed through TLC and crude proton NMR examination. To further confirm the ozonolysis 
was in fact generating the product, a quick check was performed on the crude product by 
esterification of the potentially formed carboxylic acid with diphenylmethyl (DPM) imidate 
(Scheme 3.9).42 DPM imidate has been shown to esterify carboxylic acids like 3.30 to generate the 
DPM ester 3.32 and trichloroacetamide byproduct 3.33 under mild reaction condition even in the 
presence of alcohols. 
 
Scheme 3.9: General Esterification with Diphenylmethyl Imidate 3.33 
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After acidic workup and isolation of the crude product of 3.31 generated from the 
ozonolysis reaction, the crude sample of 3.31 was dissolved in DCM followed by the addition of 
DPM imidate 3.33 and the reaction mixture was allowed to stir for 24 h (Scheme 3.10). Upon 
examination of the crude proton NMR key peaks were identified (Figure 3.9). The singlet proton 
at 6.87 ppm identifies as the proton on the methyl of the DPM ester 3.36 and the two proton peaks 
at 6.59 ppm and 5.78 ppm represent the protons of the amide trichloroacetamide byproduct 3.35. 
 
Scheme 3.10: Esterification with Diphenylmethyl Imidate 3.33 
 
 
 
 
 
 
 
Figure 3.9: Key Peaks of DPM Ester 3.36 Formation 1HNMR Peak 
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 Along with showing the formation of the DPM ester 3.36, careful monitoring of the 
esterification reaction by TLC identified the free acid 3.31. This information was then used to 
identify the formation of the acid 3.26 as the silyl enol ether 3.27 is being exposed to ozone 
generating the alcohol/carboxylic acid intermediate. Once the intermediate was observed and the 
starting material disappeared, the ozonolysis could be halted using sodium borohydride to reduce 
the ozonide.34  
The ozonolysis is a key step in the new synthetic route because it produces the necessary 
oxygen-containing functionality at C6 and C7 in different oxidation states, allowing for more a 
selective incorporation of the amine in the final product. Purification of the free acid can be 
performed by column chromatography accessing product 3.26 (Scheme 3.11). Deprotection of the 
ketal and the TBDMS group could be achieved from the hydroxy acid although the yield was low, 
possibly due to the incomplete deprotection of both the TBS protecting group and the ketal, or the 
high solubility of the free acid 3.31 in water.  
However, the ozonolysis product 3.26 can be used without purification in an intramolecular 
lactonization reaction between the free alcohol and the carboxylic acid generated in the ozonolysis 
to form the 7-member cyclic lactone 3.37. This can be accomplished in high yield using EDCl (1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide) and 4-dimethylaminopyridine in DCM.43 Once 
the lactone is formed the deprotection of the 3b alcohol and ketal can be achieved by suspending 
lactone 3.37 in methanol and adding 10% aqueous hydrochloric acid dropwise until the TLC shows 
no more starting material. The lactone 3.25 is easily separable from the minor impurities with 
column chromatography, and is not water soluble like the diol carboxylic acid 3.31 which 
facilitates the removal of impurities by extraction.  
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Scheme 3.11: Ozonolysis and Lactone 3.25 Formation  
 
Installation of the C17 exocyclic alkene was then explored. A Wittig reaction was 
performed on lactone 3.25 to generate the exocyclic olefin 3.38 using 
methyltriphenylphosphonium bromide and n-butyllithium in refluxing tetrahydrofuran (Scheme 
3.12). Initial attempts using KOH as the base proved to be of issue as no product was formed and 
starting material was lost in side reactions. This may be due to hydrolysis of the lactone. 
 
Scheme 3.12: Wittig Formation of Exocyclic Olefin 3.37 
 
 
 
 
 In an effort to conserve the key intermediate, further investigations into the Wittig reaction 
were first performed on a model system using the commercially available epiandrosterone 3.39 
(Scheme 3.13).44 The key doublet at 4.67 ppm identified the olefin protons using the n-BuLi 
conditions, providing evidence of the formation of 3.40 (Figure 3.10). 
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Scheme 3.13: Epiandrosterone 3.39 Wittig Model  
 
 
 
 
Figure 3.10: Key Model Wittig Product  3.40 1HNMR Peak 
 
 
 
 
 
 
 
With the Wittig reaction complete and alkene installed at C17, formation of the amide 3.24 
was undertaken. Attempts to break open the lactone 3.38 using ammonia in MeOH were initially 
investigated (Scheme 3.14). Treating ammonium in methanol with lactone 3.38 in a sealed tube 
with heating did not generate the amide, with the methyl ester 3.41 being identified as the major 
product from the crude 1H NMR (Figure 3.11). Although not the expected product, this did 
however prove that the lactone 3.38 could be opened to give the free alcohol. Reaction of the 
lactone 3.38 in THF while bubbling ammonia in to the system also proved to be ineffective as only 
starting material was only recovered. Alternatively, by reaction with LiNH2 (formed in situ from 
ammonia and n-BuLi), the lactone 3.38 was opened to give the amide product 3.24.  
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Scheme 3.14:Formation of Methyl Ester 3.41 and Key Amide Intermediate 3.24   
 
 
 
 
 
 
 
Figure 3.11: Key Methyl Ester 3.41 1HNMR Peak  
 
 
 
 
 
 
 
 
With the formation of the amide 3.24 a free alcohol at C6 is also generated. The newly 
formed amide intermediate 3.24 could be exposed to reducing conditions using lithium aluminum 
hydride in THF to give the free amine 3.42 (Scheme 3.15), with the free alcohols and alkene 
unaffected. Alternate methods were investigated using Red-Al as the reducing agent but a complex 
mixture of products formed. Salt formation using acetic acid and heat generated the final product 
AQX-1125 3.6. With this newly developed synthetic sequence the synthesis of AQX-1125 3.6 has 
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been reduced from the 17 step Aquinox procedure to approximately 12 linear steps, cutting the 
time and cost to produce AQX-1125 3.6.  
 
Scheme 3.15: Final Steps to AQX-1125 3.6 
 
With the newly developed synthesis for AQX-1125 3.6 in place we wished to utilize it to 
understand the role of the olefin functionality at the C17 position on the SHIP1 agonist activity. 
The synthesis of compound 3.43 (Figure 3.12) was therefore undertaken. The activity of 3.43 will 
be compared to the parent AQX-1125 3.6 to determine whether or not the alkene plays a critical 
role in the binding to the allosteric site of SHIP1. We hope that removing this functionality will 
give similar if not better activity, allowing for even quicker access to an active SHIP1 agonist for 
future development of more active compounds. 
 
Figure 3.12: Structure of Olefin-less Analog of AQX-1125 3.42 
 
 
 
 To access compound 3.43 the C17 ketone was removed from epiandrosterone. This was 
accomplished with a  Wolff-Kishner reduction45 on the commercially available ketone 3.7 in place 
of the ketal formation to remove the carbonyl functionality at the C17 position 3.44 (Scheme 3.16). 
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necessary in the original synthesis, making the synthesis of this analog even more rapid and less 
complex. The synthesis then proceeds in a similar fashion to that of the newly utilized AQX-1125 
3.6 synthesis discussed above. The alcohol 3.44 is protected as the TBS ether 3.45 followed by the 
ruthenium catalyzed allylic oxidation to give the unsaturated ketone 3.46. Purification again can 
be achieved through recrystallization as mentioned in the other route. Hydrogenation of the 
unsaturated ketone is then performed to yield the saturated carbonyl 3.47.  
 
Scheme 3.16: Synthesis of Analogue Ketone 3.46 
 
 
Formation of the silyl enol ether 3.48 was then accomplished utilizing TBSOTf and 
triethylamine (Scheme 3.17). Employing the ozonolysis reaction on 3.48 to generate the carboxylic 
acid intermediate 3.49 was followed by the formation of the lactone 3.50 with EDCl. Deprotection 
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Scheme 3.17: Synthesis of Analog Lactone 3.51 
 
Here, the Wittig originally performed on the parent compound is not necessary so amide 
formation can be directly engaged to generate amide 3.52 by addition of ammonia to the lactone 
(Scheme 3.18). Amide reduction to the free amine 3.53 using LAH reducing conditions similar to 
the parent synthesis followed by HCl salt formation generates the analog 3.43.  
 
Scheme 3.18: Final steps to AQX-1125 Analog 3.44 
 
 
 
 
 
 
 
3.4 Conclusion 
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ozonolysis reaction of a silyl enol ether to generate the key alcohol and carboxylic acid 
functionalities. The different oxidation states on carbons 5 and 6 allow for a more selective and 
controlled synthesis. Access to the lactone pseudo-protecting group allows for formation of the 
exocyclic olefin and quick formation of the amide to generate the open B ring with the necessary 
oxygen and nitrogen functionality in their correct localities. Reduction and salt formation then 
complete the synthesis of the final product AQX-1125 3.6. This synthetic sequence was also 
applied to form the analog 3.43 lacking the olefin at C17 to evaluate some key structure-activity 
relationships of the allosteric site and the necessity of the alkene. 
 
Figure 3.13: Synthesis of AQX-1125 3.6 and Analog 3.43 from Dehydroepiandrosterone 3.7 
 
 
 
 
In addition to preparing material for a standard for testing new SHIP1 agonists, structure-
activity relationships of the AQX-1125 intermediates and analogs (3.24, 3.31, 3.38, 3.51, 3.52, 
3.54) will be evaluated for SHIP1 agonist activity (Figure 3.14). These analogs will be tested 
initially in the malachite green phosphatase assay to determine if any of these molecules can 
increase SHIP1 phosphatase activity and act as SHIP1 agonists. This will help further our 
investigation into the development of more selective and active modulators. 
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Figure 3.14: SHIP1 Agonist AQX-1125 3.6 Analogs for Evaluation  
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3.5 Experimental 
General Methods: All anhydrous reactions were run under a positive pressure of argon. All 
syringes, needles, and reaction flasks required for anhydrous reactions were dried in an oven and 
cooled under an N2 atmosphere or in a desiccator. Dichloromethane and THF were dried by 
passage through an alumina column following the method of Grubbs (Pangborn, A. B.; Giardello, 
M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518). All other 
reagents and solvents were purchased from commercial sources and used without further 
purification.  
Analysis and Purification. Analytical thin layer chromatography (TLC) was performed on 
precoated glass backed plates (silica gel 60 F254; 0.25 mm thickness). The TLC plates were 
visualized by UV illumination and by staining. Solvents for chromatography are listed as 
volume:volume ratios. Flash column chromatography was carried out on silica gel (40-63 μm). 
Melting points were recorded using an electrothermal melting point apparatus and are uncorrected. 
Elemental analyses were performed on an elemental analyzer with a thermal conductivity detector 
and 2 meter GC column maintained at 50 °C. 
Identity. Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were 
recorded at 300 or 400 MHz and 75 or 100 MHz respectively. The chemical shifts are given in 
parts per million (ppm) on the delta (δ) scale. Coupling constants are reported in hertz (Hz). The 
spectra were recorded in solutions of deuterated chloroform (CDCl3), with residual chloroform (δ 
7.26 ppm for 1H NMR, δ 77.23 ppm for 13C NMR) or tetramethylsilane (δ 0.00 for 1H NMR, δ 
0.00 ppm for 13C NMR) as the internal reference. Data are reported as follows: (s = singlet; d = 
doublet; t = triplet; q = quartet; p = pentet; dd = doublet of doublets; dt = doublet of triplets; td = 
triplet of doublets; tt = triplet of triplets; qd = quartet of doublets; ddd = doublet of doublet of 
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doublets; br s = broad singlet). Where applicable, the number of protons attached to the 
corresponding carbon atom was determined by DEPT 135 NMR. Infrared (IR) spectra were 
obtained as thin films on NaCl plates by dissolving the compound in CH2Cl2 followed by 
evaporation or as KBr pellets. 
 
 
 
 
5-androsten-3β-ol-17-ethylene ketal (3.8)29 
Lit. Ref: Raymond, J.;  Han, K.;  Zhou, Y.;  He, Y.;  Noren, B.; Yee, J. G. K., Indene derivatives 
as pharmaceutical agents. Patent. Appl. 2004; EP2277848A1. 
 
Trans-dehydroandrosterone 3.7 (5.00 g, 17.3 mmol) was added to a 250 mL flame dried round-
bottom flask. 50 mL of dry Benzene was added to suspend the trans-dehydroandrosterone. p-
Toluene sulfonic acid monohydrate (0.114 g, 0.66 mmol) and ethylene glycol (5.00 mL) were then 
added to the reaction. This reaction mixture was heated to reflux under a Dean-Stark trap for 24 
hours under argon. The mixture was removed from heat and allowed to cool to rt. The excess 
benzene was removed under reduced pressure. The remaining contents were diluted with diethyl 
ether (150 mL) and washed successively with saturated NaHCO3 (2 x 75 mL) and saturated NaCl 
(75 mL). The organic layer was dried with anhydrous NaSO4 and removed under reduced pressure. 
Purification by column chromatography (30% EtOAc /70% Hexane) to yield ketal 3.8 as a white 
colored solid (0.553 g, 96%). TLC Rf  = 0.28 (30% EtOAc /70% Hexane); 1H NMR (400 MHz, 
CDCl3) δ 5.40-5.32 (m, 1H), 3.99–3.81 (m, 4H), 3.61–3.46 (m, 1H), 2.39–2.17 (m, 2H), 2.09–1.95 
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O
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(m, 2H), 1.92–1.76 (m, 3H), 1.75–1.66 (m, 1H), 1.65-1.57 (m, 2H), 1.51-1.36 (m, 6H), 1.34-1.18 
(m, 2H), 1.13-1.03 (m, 1H), 1.01 (s, 3H), 0.99-0.93 (m, 1H), 0.86 (s, 3H).  
 
 
 
 
5-androsten-3β-ol-17-ethylene ketal tert-butyldimethylsilyl ether (3.9)29 
Lit. Ref: Raymond, J.;  Han, K.;  Zhou, Y.;  He, Y.;  Noren, B.; Yee, J. G. K., Indene derivatives 
as pharmaceutical agents. Patent. Appl. 2004; EP2277848A1. 
 
 Ketal 3.8 (5.00 g, 15.0 mmol) was added to a 250 mL flame dried round-bottom flask. 27 mL of 
DMF and 27 mL of CH2Cl2 were added to dissolve the ketal. Imidazole (2.51 g, 36.8 mmol) and 
tert-butyl (chloro) dimethyl silane (3.51 g, 23.3 mmol) were then added to the reaction. This 
reaction mixture was allowed to stir at rt for 20 hours under argon. The excess solvent was removed 
under reduced pressure. The remaining contents were diluted with diethyl ether (150 mL) and 
washed successively with 5% aqueous HCl (2 x 75 mL), saturated NaHCO3 (2 x 75 mL) and 
saturated NaCl (75 mL). The organic layer was dried with anhydrous NaSO4 and removed under 
reduced pressure to yield silyl ether 3.9 as a white colored solid (6.53 g, 97%). TLC Rf  = 0.74 
(30% EtOAc /70% Hexane); 1H NMR (300 MHz, CDCl3) δ 5.36 – 5.34 (m, 1H), 3.95 – 3.84 (m, 
4H), 3.57 – 3.49 (m, 1H), 2.33 – 2.04 (m, 2H), 2.02 – 1.88 (m, 2H), 1.87-1.66 (m, 4H), 1.65-1.58 
(m, 2H), 1.52-1.37 (m, 4H), 1.35-1.19 (m, 2H), 1.01 (s, 3H), 0.89 (s, 9H), 0.86 (s, 3H), 0.06 (s, 
6H).  
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5-androsten-7-one-3β-ol 17-ethylene ketal tert-butyldimethylsilyl ether (3.10)29,38 
Lit. Ref: Raymond, J.;  Han, K.;  Zhou, Y.;  He, Y.;  Noren, B.; Yee, J. G. K., Indene derivatives 
as pharmaceutical agents. Patent. Appl. 2004; EP2277848A1. 
Burgoyne, D. L.;  Shen, Y.;  Langlands, J. M.;  Rogers, C.;  Chau, J. H.-L.;  Piers, E.; Salari, H., 
6,7-oxygenated steroids and uses related thereto. Patent. Appl. 1997; 6,046,185. 
 
tert-butyldimethylsilyl ether 3.9 (6.00 g, 13.4 mmol) was added to a 100 mL flame dried round-
bottom flask. 24 mL of cyclohexane and 3 mL of water were added to dissolve the ketal. 
Ruthenium trichloride hydrate (0.022 g, catalytic) was then added to the reaction. 70% tert-Butyl 
hydroperoxide (14 mL) was added drop wise. This reaction stirred for 22 hours under argon. Then 
an additional 5 mL of cyclohexane was added and this was allowed to stir at rt for 2 additional 
hours. The mixture was diluted with ethyl acetate (100 mL) and filtered over celite. The collected 
organic was washed successively with 25% aqueous Na2SO4 (2 x 75 mL) and saturated NaCl (75 
mL). The organic layer was dried with anhydrous NaSO4 and removed under reduced pressure. 
Recrystallized using hot EtoAc to yield the unsaturated ketone 3.10 as a pale-yellow solid (3.34 g, 
54%). 1H NMR (400 MHz, CDCl3) δ 5.67 (s, 1 H), 3.99 – 3.74 (m, 4 H), 3.68 – 3.55 (m, 1 H), 
2.56 – 2.433(m, 3H), 2.29 – 2.18 (m, 1H), 2.06-1.88 (m, 2H), 1.87-1.73 (m, 3H), 1.69-1.59 (m, 
2H), 1.54-1.38 (m, 5H), 1.23-1.15 (m, 4H), 0.89 (s, 9 H), 0.86 (s, 3 H), 0.06 (s, 6 H).  
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5-androsta-7-one-3β-ol 17-ethylene ketal tert-butyldimethylsilyl ether (3.28)29 
Lit. Ref: Raymond, J.;  Han, K.;  Zhou, Y.;  He, Y.;  Noren, B.; Yee, J. G. K., Indene derivatives 
as pharmaceutical agents. Patent. Appl. 2004; EP2277848A1. 
 
To a 250 mL flame-dried round bottom flask, 3.10 (2.13g, 4.62 mmol) was dissolved in 140 mL 
of ethyl acetate. 10% Pd/C (0.45 g) was added to the reaction. This was placed under vacuum until 
bubbling occurred in which a hydrogen balloon was added. This was allowed to stir for 20 hours 
at rt. The reaction was then filtered through celite, rinsing with ethyl acetate. This was concentrated 
under reduced pressure to yield ketone 3.28 as a white colored solid (2.02 g, 94%). mp = 198.5 – 
200.3°C; TLC Rf  = 0.30 (10% EtOAc /90% Hexane); IR (neat) 2979, 1698, 1091 cm-1; 1H NMR 
(400 MHz, CDCl3) 3.98 – 3.78 (m, 4 H), 3.61 – 3.48 (m, 1 H), 2.33 (t, J = 11.8 Hz, 2 H), 2.29-
2.18 (m, 1H), 2.04-1.88 (m, 2H), 1.87-1.72 (m, 2H), 1.76-1.67 (m, 2H), 1.66-1.61 (m, 1H), 1.51-
1.45 (m, 5H), 1.39-1.18 (m, 4H), 1.07 (s, 3H), 1.05-0.92 (m, 1H), 0.87 (s, 9H), 0.83 (s, 3H), 0.04 
(s, 6H).  
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5-androsta -7 – tert-butyldimethyl oxysilane -3β-ol 17-ethylene ketal tert-butyldimethylsilyl 
enol ether (3.27)34 
Lit. Ref: Duffy, B., Thioetherification and etherification utilizing trichloroacetimidates under 
thermal conditions & progress towards an efficient synthesis of AQX-1125. Syracuse University 
Dissertations, Department of Chemistry 2016. 
3.28 (3.30 g, 7.13 mmol) was dissolved in 65 mL of CH2Cl2.  38.8 mL of triethylamine (278 mmol) 
was added drop wise at 0˚C. This was allowed to stir at this temperature for 15 minutes. Tert-
butyldimethylsilyl trifluoromethane sulfonate (9.80 mL, 42.8 mmol) was then added to the 
reaction, maintaining 0°C. This reaction mixture was placed at rt and allowed to stir for 20 hours 
under argon. This was re-placed at 0°C and isopropyl alcohol (1.1 mL) was then added. The 
reaction was then diluted with DCM (150 mL) and saturated NaHCO3 (150 mL). The aqueous 
phase was extracted 2x with DCM (100 mL) collected and the organic layer was washed with 
saturated NaHCO3 (1x 100 mL) and brine (1x 100 mL) (This was concentrated under reduced 
pressure and subjected to column chromatography (10% EtOAc/90% Hexane) to yield silyl enol 
ether 3.27 as a pale-yellowish solid (3.40 g, 83%). TLC Rf  = 0.58 (10% EtOAc /90% Hexane); 1H 
NMR (300 MHz, CDCl3) δ 4.38 (s, 1H), 3.96 – 3.79 (m, 4H), 3.58 (septet, J = 15.5, 10.5, 5.25 Hz, 
1H), 1.99 – 1.85 (m, 4 H), 1.82 – 1.57 (m, 6 H), 1.52 – 1.45 (m, 2 H), 1.42 – 1.15 (m, 4 H), 1.12-
0.97 (m, 2H),  0.91 (s, 9 H), 0.88 (s, 12 H), 0.74 (s, 3H), 0.12 (d, J = 4.35 Hz, 6H), 0.06 (s, 6H).  
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(7a'S)-5'-((1R,4S)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-1-methylcyclohexyl)-
7a'-methyloctahydrospiro[[1,3]dioxolane-2,1'-indene]-4'-carboxylic acid (3.26) 
tert-butyldimethylsilyl enol ether 3.27 (4.41 g, 7.64 mmol) was dissolved in methanol (122 mL) 
and CH2Cl2 (122 mL) and was treated with excess O3 at -78 °C until the solution turned blue. After 
purging with argon, the blue color dissipated. This was placed at 0 °C and sodium borohydride 
(0.866 g, 22.9 mmol) was added. This was then placed at rt and allowed to stir for 20 hours. 
Another equivalent of NaBH4 was added and stirred for another 3 hours. After the solvent was 
evaporated on a rotary evaporator, DCM was added (150 mL) and water (150 mL). The solution 
foamed from the evolution of H2 gas so 10% HCl was added drop wise until the foaming stopped. 
The DCM layer was removed and the aqueous layer extracted with CH2Cl2 (3 × 75 mL). The 
organic layers were collected and washed with saturated NaCl (2x 75 mL). The organic layer was 
dried with anhydrous NaSO4 and removed under reduced pressure. Purification by column 
chromatography (10% MeOH/ 90% DCM)) to yield acid 3.26 as a cream colored solid (2.39 g, 
63%). TLC Rf  = 0.47 (10% MeOH/ 90% DCM); IR (neat) 3404, 1701, 1053 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.57 (bs, 1 H), 3.96-3.77 (m, 4 H), 3.71 (d, J = 9.2 Hz, 1 H), 3.49 (bs, 1 H), 3.25 
(s, 1 H), 2.29 (t, J = 10.8 Hz, 1 H), 2.04-1.82 (m, 4 H), 1.81-1.69 (m, 3 H), 1.68-1.45 (m, 4 H), 
1.44-1.18 (m, 7 H), 0.86 (s, 12 H), 0.79 (s, 3 H) 0.03 (s, 6 H). 13C NMR (100 MHz, CDCl3): δ 
182.1, 118.7, 71.0, 65.2, 64.6, 62.6, 47.5, 45.5, 45.1, 45.0, 42.1, 37.7, 34.4, 33.6, 31.2, 29.9, 25.9, 
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22.9, 20.7, 19.3, 18.2, 13.7, -4.58. Anal calcd for C18H28O4: C, 65.28; H, 9.74 Found: C, 65.25; H, 
9.76.  
 
 
 
 
 
 
 
 
(7aS)-5-[(1R,4S)-4-Hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl]-7a-methyl-1-oxo-
2,3,3a,4,5,6,7,7a-octahydroindene-4-carboxylic acid (3.31) 
Carboxylic acid 3.26 (0.399 g, 0.803 mmol) was dissolved in tetrahydrofuran (13 mL) and was 
treated with 4.5 mL of 10% HCl at rt for 5h. The solution was extracted with EtoAc (3 × 100 mL). 
The organic layers were collected and washed with saturated NaCl (2x 50 mL). The organic layer 
was dried with anhydrous NaSO4 and removed under reduced pressure to yield acid 3.31 as a white 
solid (0.090 g, 33%). TLC Rf  = 0.20 (10% MeOH/ 90% DCM); IR (neat) 3441, 3293, 1736, 1696 
cm-1; 1H NMR (400 MHz, MeOD) δ 3.73 (d, J = 8.00 Hz, 1H), 3.59-3.40 (m, 1H), 3.13 (t, J = 
10.3 Hz, 1H), 2.58-2.42 ( m, 2H), 2.22-2.06 (m, 2H), 2.05-1.96 (m, 1H), 1.95-1.88 (m, 1H), 1.87-
1.74 (m, 5H), 1.74-1.62 (m, 2H), 1.61-1.47 (m, 2H), 1.44-1.25 (m, 3H), 0.96 (s, 3H), 0.88 (s, 3H). 
13C NMR (100 MHz, MeOD): δ 178.0, 69.3, 60.55, 48.2, 46.1, 45.8, 44.1, 41.8, 36.9, 34.4, 33.0, 
29.8, 29.5, 21.5, 19.8, 17.8, 11.6. Anal calcd for C18H28O4: C, 67.43; H, 8.94 Found: C, 67.77; H, 
8.62.  
 
 
 
 
HO
H
H
H
H
HO
HO
O
3.31
O
 114 
 
 
 
 
 
 
 
 (2'R,5'S,16'S)-5'-((tert-butyldimethylsilyl)oxy)-2',16'-dimethylspiro[1,3-dioxolane-2,15'-
[9]oxatetracyclo[9.7.0.02,7.012,16]octadecan]-10'-lactone (3.37) 
Carboxylic acid 3.26 (1.50 g, 3.02 mmol) was dissolved in 45 mL of DCM followed by the addition 
of DMAP (0.074 g, 0.604 mmol). After stirring for 5 minutes, 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (0.94 g, 6.04 mmol) was then added. This was allowed to stir 
at rt for 24 hours. The reaction was diluted with DCM (150 mL) and washed successively with 
saturated NaHCO3 (2 x 50 mL), 10% aqueous HCl (2 x 50 mL), and saturated NaCl (50 mL). The 
organic layer was dried with anhydrous MgSO4 and solvent removed under reduced pressure. This 
was subjected to column chromatography using (20% EtOAc/80% Hexane) to yield lactone 3.37 
as a white solid (1.39 g, 96%). TLC Rf  = 0.51 (20% EtOAc /80% Hexane); IR (neat) 2979, 1716, 
1095, 1044 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.31 (dd, J = 12.7, 7.2 Hz, 1 H), 3.98-3.80 (m, 
4H), 3.60 (d, J = 12.7 Hz, 1H), 3.57-3.46 (m, 1H), 2.56 (t, J = 2.6 Hz, 1H), 2.36-2.21 (m, 1H), 
2.00, 1.76 (m, 5H), 1.75-1.58 (m, 3H), 1.56-1.48 (m, 2H), 1.45-1.24 (m, 5H), 1.23-1.05 (m, 2H), 
1.03 (s, 3H), 0.88 (s, 9H), 0.84 (s, 3H), 0.05 (s, 6H). 13C NMR (100 MHz, CDCl3): δ 176.5, 118.7, 
70.9, 68.2, 65.2, 64.5, 47.2, 46.6, 44.7, 44.0, 42.3, 38.6, 37.6, 37.3, 33.5, 31.3, 29.2, 25.7, 24.7, 
21.5, 18.2, 12.9, 13.4, -4.67.  
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((2R,5S,16S)-5-Hydroxy-2,16-dimethyl-9-oxatetracyclo[9.7.0.02,7.012,16]octadecane-15-one-
10’-lactone (3.25) 
Lactone 3.37 (0.200 g, 0.42 mmol) was added to a 100 mL flame dried round-bottom flask. 10.0 
mL of methanol and 6.0 mL of 10% aq. HCl was added to the solution. This reaction mixture was 
allowed to stir at rt for 4 hours. The reaction mixture was concentrated down and the contents 
diluted with ethyl acetate (75 mL) and water (75 mL). The aqueous phase was extracted with ethyl 
acetate (2 x 50 mL) and the collected organic was washed successively with saturated aqueous 
NaHCO3 (2 x 50 mL) and NaCl (1 x 50 mL), The organic layer was dried with anhydrous MgSO4 
and removed under reduced pressure. Purification through column chromatography (80% EtOAc: 
20% Hexane) yielded lactone 3.25 as a white colored solid (0.11 g, 82%). TLC Rf  = 0.34 (100% 
EtOAc); IR (neat) 3478, 1739, 1697 cm-1;1H NMR (400 MHz, CDCl3) δ 4.37 (q, J = 7.75 Hz, 1 
H), 3.67 (d, J = 13.1 Hz, 1 H), 3.64-3.56 (m, 1 H), 2.74 (t, J = 10.7 Hz, 1 H), 2.51-2.38 (m, 1 H), 
2.26-2.00 (m, 3 H), 1.99-1.86 (m, 2 H), 1.86-1.72 (m, 3H), 1.66-1.56 (m, 2H), 1.51-1.22 (m, 6H), 
1.13-1.02 (m, 1H), 1.06 (s, 3H), 0.86 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 219.7, 175.9, 69.9, 
68.3, 47.2, 46.4, 45.9, 45.8, 41.6, 38.8, 37.2, 36.6, 35.4, 30.7, 30.3, 23.6, 21.6, 13.2, 13.2; Anal 
calcd for C18H28O4: C, 71.22; H, 8.81 Found: C, 71.26; H, 8.64. 
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 (2R,5S,16S)-5-Hydroxy-2,16-dimethyl-15-methylene-9- 
oxatetracyclo[9.7.0.02,7.012,16]octadecan-10’-lactone (3.38) 
Methyltriphenylphosphonium bromide (10.6 g, 29.6 mmol) was suspended in 56.7 mL dry THF 
under argon. n-BuLi (11.2 mL, 2.5 M) was added dropwise to the stirring solution to generate the 
ylide. This stirred for 15 min at rt before being heated to 40˚C. Lactone 3.25 (1.90 g, 5.93 mmol) 
was dissolved in 69.3 mL dry THF and added dropwise into the stirring reaction. The temperature 
was increased to reflux and the reaction ran for 24 h. The flask was then removed from heat and 
allowed to cool down to rt before water (75.0 mL) was added dropwise to quench the reaction. 
Ethyl acetate (100 mL) and water (75.0 mL) was added and the layers separated. The aqueous 
phase was extracted with ethyl acetate (2 x 100 mL). The collected organic phase was washed with 
water (2 x 75 mL) followed by brine (2 x 75100 mL). The organic layer was dried with anhydrous 
MgSO4 and removed under reduced pressure. This was subjected to column chromatography using 
(25% Et2O/75% EtOAc) to yield lactone 3.38 as a white solid (1.28 g, 67%). TLC Rf  = 0.51 (100% 
EtOAc); IR (neat) 3510, 3074, 1701, 1675 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.65 (d, J = 8.93 
Hz, 2 H), 4.33 (dd, J = 12.6, 7.80 Hz, 1 H), 3.68-3.50 (m, 2 H), 2.59 (t, J = 10.8 Hz, 1 H), 2.52-
2.39 (m, 1 H), 2.37-2.22 (m, 1 H), 2.11-2.01 (m, 1H), 1.98-1.67 (m, 7 H), 1.66-1.46 (m, 2 H), 1.44-
1.12 (m, 5 H), 1.03 (s, 4 H), 0.76 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 177.0, 160.0, 101.8, 
69.9, 68.2, 48.4, 47.1, 46.5, 42.0, 41.7, 38.7, 37.3, 36.6, 34.2, 30.7, 28.8, 26.1, 22.0, 17.9, 13.2. 
Mass Spec m/z C20H30O3 Exact Mass 318.2195; Observed 318.2192. 
 
OHO
H
H
H
H
O
3.38
 117 
 
 
 
 
 
 
 
(3aS,4R,5S,7aS)-5-[(1R,2S,4S)-4-Hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl]-7a-
methyl-1-methylene-2,3,3a,4,5,6,7,7a-octahydroindene-4-carboxamide (3.24) 
A solution of ammonia in THF (5.3 mL, 0.5 M) was cooled to -78˚C. n-BuLi (1.0 mL, 2.5 M) was 
added dropwise and allowed to stir for 30 min. Lactone 3.38 (0.169 g, 0.53 mmol) was dissolved 
in a solution of 2.0 mL dry THF and added dropwise into the reaction before allowing the reaction 
to warm to rt The reaction continued for 24 hours. The reaction was diluted with NH4+Cl- (50 mL) 
and extracted successively with EtOAc (2 x 75 mL). The collected organic was washed with 
saturated NaCl (2 x 50 mL). The organic layer was dried with anhydrous MgSO4 and solvent 
removed under reduced pressure. This was subjected to column chromatography using (90% 
EtoAc/10% MeOH) to yield amide 3.24 as a white solid (0.101 g, 57%). TLC Rf  = 0.51 (80% 
EtOAc /20% MeOH); 1H NMR (300 MHz, CD3OD) δ 4.69 (s, 2 H), 3.77 (dd, J = 10.7, 3.1 Hz, 1 
H), 3.55-3.39 (m, 1 H), 3.12 (t, J = 10.7 Hz, 1 H), 2.59-2.46 (m, 1 H), 2.41 (t, J = 10.4 Hz, 1 H), 
2.34-2.07 (m, 2 H), 2.03-1.95 (m, 1H), 1.94-1.74 (m, 4H), 1.73-1.55 (m, 3H), 1.54-1.30 (m, 6H), 
0.97 (s, 3H), 0.84 (s, 3H). 13C NMR (75MHz, CDCl3): δ 180.4, 160.4, 100.9, 70.0, 60.9, 51.5, 
44.6, 44.5, 42.7, 42.3, 37.4, 35.1, 33.5, 30.4, 29.9, 28.5, 24.7, 20.9, 18.3, 16.9. Anal calcd for 
C18H28O4: C, 71.6; H, 9.92; N, 4.18 Found: C, 71.20; H, 9.63; N, 4.28. 
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(1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylene-2,3,3a,4,5,6,7,7a-
octahydroinden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexanol (3.42)  
Amide 3.24 (0.350 g, 1.25 mmol) was dissolved in 12.0 mL of THF and cooled to 0˚C. LAH (25.0 
mL, 1.0M in THF) was added dropwise to the stirring solution. The temperature was increased to 
reflux for 20 h. The reaction was cooled to rt and diluted with THF before being cooled to 0˚C. 
Fieser method was used to work up the reaction. The filtered product was dried with MgSO4 and 
concentrated down to give the crude amine. Purification through column chromatography (10% 
methanol: 89% EtOAc: 1% NH4+OH-) yield the amine 3.42 as a white gum (0.164 g, 49%). TLC 
Rf  = 0.23 (89% EtOAc /10% MeOH/ 1% NH4OH); 1H NMR (300 MHz, MeOD) δ 4.65 (s, 2H), 
3.75(dd, J = 10.8, 2.17 Hz, 1H), 3.56-3.39 (m,1H), 3.25-3.00 (m, 2H), 2.74 (d, J = 14.4 Hz, 1H), 
2.63-2.43 (m, 1H), 2.42-2.24 (m, 1H), 2.32-2.10 (m, 1H), 1.94-1.74 (m, 5H), 1.74-1.21 (m, 11H), 
1.11 (s, 3H), 0.84 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 161.2, 101.2, 70.2, 62.8, 49.9, 43.3, 
41.9, 38.7, 37.1, 35.9, 34.4, 31.1, 30.7, 29.7, 29.1, 24.7, 23.2, 21.1, 18.3, 14.1.  
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(1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylene-2,3,3a,4,5,6,7,7a-
octahydroinden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexanol ammonium acetate 
AQX-1125 (3.6) 
Lit. Ref: Raymond, J.;  Han, K.;  Zhou, Y.;  He, Y.;  Noren, B.; Yee, J. G. K., Indene derivatives 
as pharmaceutical agents. Patent. Appl. 2004; EP2277848A1. 
 
Amine 3.42 (0.100 g, 0.311 mmol) was dissolved in 5.0 mL 80% Acetic acid and heated to 40˚C 
while stirring for 1 ½ hr. The reaction was cooled to rt before 10.0 mL toluene was added. The 
solution was concentrated down 3 times with toluene and the residue was washed with diethyl 
ether 3 times. to yield amine salt 3.6 as a white solid (0.052 g, 43%). 1H NMR (300 MHz, MeOD) 
δ 4.69 (s, 2 H), 3.73 (dd, J = 11.0, 2.56 Hz, 1 H), 3.59-3.42 (m, 1 H), 3.17 (t, J = 10.4 Hz, 1 H), 
3.06 (dd, J = 13.9, 2.78 Hz, 1 H), 2.69-2.50 (m, 1 H), 2.45-2.27 (m, 1 H), 2.26-2.13 (m, 1 H), 1.99-
1.94 (m, 1 H), 1.93 (s, 3 H), 1.92-1.79 (m, 5 H), 1.68-1.56 (m, 2 H), 1.55-1.38 (m, 4 H), 1.37-1.21 
(m, 4 H), 1.19 (s, 3 H), 0.87 (s, 3 H). 13C NMR (75 MHz, MeOD): δ 160.6, 100.6, 69.6, 61.3, 49.7, 
44.2, 43.4, 43.3, 41.1, 36.9, 36.7, 35.4, 33.7, 30.6, 28.6, 24.1, 22.7, 20.3, 17.2. Mass Spec m/z 
C20H36NO2 Exact Mass 322.274056; Observed 322.274010. Anal calcd for C18H28O4: C, 69.25; 
H, 10.30; N, 3.61 Found: C, 69.28; H, 10.25; N, 3.30. 
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5-androsten-3β-ol (3.44)46 
Lit. Ref: Mori, K.;  Nakayama, T.; Sakuma, M., Synthesis of some analogues of blattellastanoside 
A, the steroidal aggregation pheromone of the German cockroach. Bioorg. Med. Chem. 1996, 4, 
401-408. 
 
KOH (4.90 g, 86.7 mmol) was added to 25 mL diethylene glycol and heated until dissolved with 
a heat gun. Once the solution of KOH in diethylene glycol cooled to rt dehydroepiandrosterone 
3.7 (5.00 g, 17.3 mmol) and hydrazine hydrate (3.4 mL, 69.3 mmol) were added. With a reflux 
condenser attached the solution was heated to 245˚C and stirred continuously for 24 h. The 
condenser was removed and a distillate column attached to distill off diethylene glycol. The 
reaction was then cooled to rt and 100 mL MTBE and 100 mL brine were added and the solution 
stirred overnight. The aqueous phase was extracted with MTBE (10 x 60 mL). The collected 
organic phase was washed with brine (5 x 60 mL), dried with sodium sulfate, and concentrated 
down. Column chromatography (30% EtOAc/70% Hexane) yielded alcohol 3.44 as a white 
colored solid (4.59 g, 96%). TLC Rf  = 0.24 (30% EtOAc /70% Hexane); 1H NMR (400 MHz, 
CDCl3) δ 5.39 – 5.31 (m, 1H), 3.58 – 3.48 (m, 1H), 2.39-2.13 (m, 2H), 2.06-1.97 (m, 1H), 1.90-
1.79 (m, 2H), 1.78-1.71 (m, 1H), 1.70-1.63 (m, 2H), 1.62-1.59 (m, 1H), 1.54-1.51 (m, 1H), 1.50-
1.47 (m, 1H), 1.46-1.37 (m, 3H), 1.31-1.05 (m, 5H), 1.02 (s, 3H), 0.99-0.84 (m, 3H), 0.72 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 140.8, 121.7, 71.8, 54.9, 50.5, 42.3, 40.6, 40.3, 38.7, 37.4, 36.7, 
32.2, 32.1, 231.7, 25.6, 21.1, 20.5, 19.4, 17.3. 
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5-androsten-3β-ol- tert-butyldimethylsilyl ether (3.45)24 
3.44 (3.64 g, 13.3 mmol) was added to a 250 mL flame dried round-bottom flask. 44 mL of DMF 
and 44 mL of CH2Cl2 were added to dissolve the ketal. Imidazole (2.21 g, 32.5 mmol) and tert-
butyl (chloro) dimethyl silane (3.10 g, 20.6 mmol) were then added to the reaction. This reaction 
mixture was allowed to stir at rt for 20 hours under argon. The excess solvent was removed under 
reduced pressure. The remaining contents were diluted with diethyl ether (150 mL) and washed 
successively with 5% aqueous HCl (2 x 75 mL), saturated NaHCO3 (2 x 75 mL) and saturated 
NaCl (75 mL). The organic layer was dried with anhydrous NaSO4 and removed under reduced 
pressure to yield the silyl ether 3.45 as a white colored solid (4.67 g, 91%). TLC Rf  = 0.89 (10% 
EtOAc/90% Hexane); IR (neat) 2952, 1091 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.32 (d, J = 5.14, 
1H), 3.48 (septet, J = 15.8, 10.8, 4.6, 1H), 2.32 – 2.22 (m, 1H), 2.17 (ddd, J= 13.1, 4.9, 2.1, 1H), 
2.06 – 1.96 (m, 1H), 1.82 (dt, J = 16.7, 3.5, 1H), 1.78 – 1.62 (m, 4H), 1.61-1.55 (m, 2H), 1.54-
1.50 (m. 2H), 1.49-1.34 (m, 3H), 1.27-1.10 (m, 3H), 1.09-1.03 (dd, J = 13.6, 3.7, 1H), 1.01 (s, 3H), 
0.99-0.92 (dd, J = 11.8, 5.2, 1H), 0.91-0.86 (m, 10H), 0.71 (s, 3H), 0.06 (s, 6H). 13C NMR (100 
MHz, CDCl3): δ 141.6, 121.2, 72.7, 54.9, 50.54, 42.85, 40.6, 40.3, 38.8, 37.5, 36.8, 32.3, 32.2, 
32.1, 25.9, 25.6, 21.1, 20.5, 19.5, 18.3, 17.3, -4.6. 
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5-androsten-7-one-3β-ol tert-butyldimethylsilyl ether (3.46)24 
tert-butyldimethylsilyl ether 3.46 (9.02 g, 23.2 mmol) was added to a 250 mL flame dried round-
bottom flask. 37 mL of cyclohexane and 4.5 mL of water were added to dissolve the ketal. 
Ruthenium trichloride hydrate (0.039 g, catalytic) was then added to the reaction. 70% tert-Butyl 
hydroperoxide (26 mL) was added drop wise. This reaction stirred for 24 hours under argon. Then 
an additional 5 mL of cyclohexane was added and this was allowed to stir at rt for 2 additional 
hours. The mixture was diluted with ethyl acetate (100 mL) and washed successively with 25% 
aqueous Na2SO4 (2 x 60 mL) and saturated NaCl (60 mL). The organic layer was dried with 
anhydrous NaSO4 and removed under reduced pressure. Recrystallization by hot EtOAc to yield 
the unsaturated ketone 3.46 as a pale-yellow solid (2.35 g, 25%). TLC Rf  = 0.89 (100% Hexane); 
IR (neat) 2938, 1656, 1058 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.68 (d, J = 1.34, 1H), 3.60 (septet, 
J = 15.8, 10.3, 5.5, 1H), 2.57-2.31 (m, 3H), 2.19 (t, J = 11.2, 1H), 1.92 (dt, J = 13.7, 3.52, 1H), 
1.86-1.78 (m, 1H), 1.74 (dt, J = 13.0, 3.26, 1H), 1.69-1.64 (m, 2H), 1.63-1.57 (m, 3H), 1.55-1.47 
(m, 2H), 1.46-1.28 (m, 2H), 1.27-1.21 (m, 1H), 1.19 (s, 3H), 1.17-1.07 (m, 2H), 0.89 (s, 9H), 0.72 
(s, 3H), 0.66 (s, 6H). 13C NMR (100 MHz, CDCl3): δ 202.3, 166.2, 125.7, 71.3, 50.3, 48.1, 45.8, 
42.6, 41.3, 39.2, 38.5, 37.8, 36.5, 31.8, 27.6, 25.8, 21.3, 20.6, 18.1, 17.3, 17.2, -4.64. Anal calcd 
for C25H42O2Si: C, 74.57; H, 10.51 Found: C, 74.62; H, 10.42. 
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5-androsta-7-one-3β-ol tert-butyldimethylsilyl ether (3.47) 
To a 250 mL flame-dried round bottom flask, tert-butyldimethylsilyl ether 3.46 (2.25g, 5.58 mmol) 
was dissolved in 154 mL of ethyl acetate. 10% Pd/C (0.26 g) was added to the reaction. This was 
placed under vacuum until bubbling occurred in which a hydrogen balloon was added. This was 
allowed to stir for 20 hours at rt. The reaction was then filtered through celite, rinsing with ethyl 
acetate. This was concentrated under reduced pressure to yield ketone 3.47 as a white colored solid 
(2.14 g, 95%). mp = 198.5 – 200.3°C; TLC Rf  = 0.67 (15% EtOAc /85% Hexane); IR (neat) 2929, 
1707, 1096 cm-1; 1H NMR (400 MHz, CDCl3) 3.55 (septet, J = 15.1, 10.5, 4.17, 1H), 2.44-2.18 
(m, 3H), 2.07-1.95 (m, 1H), 1.78-1.68 (m, 3H), 1.67-1.57 (m, 3H), 1.54-1.37 (m, 6H), 1.36-1.21(m, 
2H), 1.20-1.10 (m, 2H), 1.08 (s, 3H), 1.07-0.92 (m, 2H), 0.88 (s, 9H), 0.68 (s, 3H) 0.04 (s, 6H). 
13C NMR (100 MHz, CDCl3): δ 212.3, 71.5, 55.8, 50.4, 47.0, 46.9, 46.1, 40.8, 39.4, 38.5, 37.8, 
36.3, 36.1, 31.6, 26.3, 25.9, 21.9, 20.6, 18.2, 17.4, 11.9, -4.63. Anal calcd for C25H44O2Si: C, 74.20; 
H, 10.96 Found: C, 74.08; H, 10.84. 
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5-androsta -7 – tert-butyldimethyl oxysilane -3β-ol tert-butyldimethylsilyl ether (3.48) 
Ketone 3.47 (0.76 g, 1.87 mmol) was dissolved in 15.3 mL of CH2Cl2.  10.2 mL of triethylamine 
(74.0 mmol) was added drop wise at 0˚C. This was allowed to stir at this temperature for 15 
minutes. tert-butyldimethylsilyl trifluoromethane sulfonate (2.15 mL, 9.37 mmol) was then added 
to the reaction, maintaining 0°C. This reaction mixture was placed at rt and allowed to stir for 20 
hours under argon. This was re-placed at 0°C and isopropyl alcohol (1.1 mL) was then added. The 
reaction was then diluted with DCM (100 mL) and saturated NaHCO3 (50 mL). The aqueous phase 
was extracted 2x with DCM (100 mL) collected and the organic layer was washed with saturated 
NaHCO3 (1x 50 mL) and brine (1x 50 mL) and dried over MgSO4 (This was concentrated under 
reduced pressure and subjected to column chromatography (1% EtOAc/99% Hexane) to yield silyl 
enol ether 3.48 as a pale yellowish-white colored solid (0.85 g, 87%). TLC Rf  = 0.58 (1% EtOAc 
/99% Hexane); IR (neat) 2928, 1082 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.41 (s, 1H), 3.59 (septet, 
J = 15.3, 10.5, 5.27, 1H), 1.98-1.78 (m, 3H), 1.77-1.68 (m, 2H), 1.67-1.56 (m, 3H), 1.52-1.45 (m, 
2H), 1.44-1.18 (m, 5H), 1.17-0.96 (m, 5H), 0.92 (s, 9H), 0.89 (s, 9H), 0.74 (s, 3H), 0.73 (s, 3H), 
0.12 (d, J = 8.13, 6H), 0.06 (d, J = 0.82, 6H). 13C NMR (100 MHz, CDCl3): δ 152.6, 108.5, 72.2, 
54.6, 52.4, 43.6, 42.5, 42.3, 39.8, 39.4, 34.3, 31.9, 28.5, 26.1, 25.9, 21.5, 29.2, 18.2, 18.1, 11.3, -
3.89, -4.22, -4.57. Mass Spec m/z C31H58O2Si2 Exact Mass 518.3975; Observed 518.3975. 
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(7aS)-5-[(1R,4S)-4-((tert-butyldimethylsilyl)oxy)-1-methylcyclohexyl]-7a-methylperhydro-
1H-indene-4-carboxylic acid (3.49) 
Silyl enol ether, 3.48 (1.30 g, 2.50 mmol) was dissolved in methanol (40 mL) and CH2Cl2 (40 mL) 
and was treated with excess O3 at -78 °C until the solution turned blue. After purging with argon, 
the blue color dissipated. This was placed at 0 °C and sodium borohydride (0.38 g, 10.0 mmol) 
was added. This was then placed at rt and allowed to stir for 20 hours. Another equivalent of 
NaBH4 was added and stirred for another 3 hours. After the solvent was evaporated on a rotary 
evaporator, DCM was added (50 mL) and water (50 mL). The DCM layer was removed and the 
aqueous layer extracted with CH2Cl2 (3 × 50 mL). The organic layers were collected and washed 
with saturated NaCl (2x 50 mL). The organic layer was dried with anhydrous MgSO4 and removed 
under reduced pressure to yield acid 3.49 as a cream colored foam (0.659 g, 60%). TLC Rf  = 0.49 
(10% MeOH/ 90% DCM). 1H NMR (400 MHz, CDCl3) δ 3.75 (dd, J = 10.9, 3.1 Hz, 1H), 3.53 
(bs, 1H), 3.31 (t, J = 8.9 Hz, 1H), 2.29 (t, J = 10.9 Hz, 1H), 2.07-1.89 (m, 3H), 1.80-1.73 (m, 3H), 
1.71-1.65 (m, 3H), 1.64-1.57 (m, 3H), 1.52-1.46 (m, 2H), 1.42 (t, J = 7.1 Hz, 3H), 1.35-1.18 (m, 
5H), 0.90 (s, 3H), 0.89 (s, 9H), 0.71 (s, 3H), 0.06 (s, 6H).  
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 (2R,5S,16S)-5-((tert-butyldimethylsilyl)oxy)-2,16-dimethyl-9-
oxatetracyclo[9.7.0.02,7.012,16]octadecan-10-lactone (3.50) 
Carboxylic acid 3.49 (0.27 g, 0.62 mmol) was dissolved in 9.2 mL of DCM followed by the 
addition of DMAP (0.015 g, 0.12 mmol). After stirring for 5 minutes, 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (0.19 g, 1.23 mmol) was then added. This was allowed to stir 
at rt for 24 hours. The reaction was diluted with DCM (75 mL) and washed successively with 
saturated NaHCO3 (2 x 25 mL), 10% aqueous HCl (2 x 25 mL), and saturated Aq. NaCl (25 mL). 
The organic layer was dried with anhydrous MgSO4 and solvent removed under reduced pressure. 
This was subjected to column chromatography using (20% EtOAc/80% Hexane) to yield protected 
lactone 3.50 as a white solid (0.24 g, 92%). TLC Rf  = 0.42 (10% EtOAc /90% Hexane); IR (neat) 
2972, 1732, 1093 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.33 (dd, J = 12.9, 7.54, 1H), 3.61 (d, J = 
12.8, 1H), 3.53 (septet, J = 15.4, 10.7, 4.72, 1H), 2.50 (t, J = 11.1, 1H), 1.95-1.83 (m, 2H), 1.82-
1.74 (m, 2H), 1.73-1.60 (m, 5H), 1.52-1.15 (m, 8H), 1.12-1.05 (m, 1H), 1.03 (s, 3H), 1.02-0.97 
(m, 1H), 0.87 (s, 9H), 0.71 (s, 3H), 0.05 (s,6H). 13C NMR (100 MHz, CDCl3): δ 177.6, 70.9, 68.3, 
48.5, 47.4, 46.7, 41.9, 39.8, 38.7, 38.7, 37.5, 37.3, 37.2, 31.3, 27.5, 25.9, 22.2, 19.9, 18.2, 16.7, 
13.3, -4.7. Mass Spec m/z C25H44O3Si Exact Mass 420.3060; Observed 420.3054. 
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(2R,5S,16S)-5-Hydroxy-2,16-dimethyl-9-oxatetracyclo[9.7.0.02,7.012,16]octadecan-10-one 
(3.51) 
Lactone 3.50 (0.19 g, 0.19 mmol) was added to a 100 mL flame dried round-bottom flask. 5.0 mL 
of methanol and 6.0 mL of 10% aq. HCl was added to reaction. The reaction mixture was allowed 
to stir at rt for 4 hours. The solution was concentrated down and the contents diluted with ethyl 
acetate (50 mL) and water (50 mL). The aqueous phase was extracted with ethyl acetate (2 x 50 
mL) and the collected organic was washed successively with saturated aqueous NaHCO3 (2 x 25 
mL) and NaCl (1 x 25 mL), The organic layer was dried with anhydrous MgSO4 and removed 
under reduced pressure. Purification through column chromatography (80% EtOAc: 20% Hexane) 
yielded lactone 3.51 as a white colored solid (0.123 g, 89%). TLC Rf  = 0.42 (50% EtOAc /50% 
Hexane); IR (neat) 3276, 1733, 1032 cm-1;  1H NMR (300 MHz, CDCl3) δ 4.34 (dd, J = 12.9, 7.9 
Hz, 1 H), 3.67-3.49 (m, 2 H), (t, J = 10.6 Hz, 1 H), 1.96-1.86 (m, 2 H), 1.85-1.72  (m, 5 H), 1.70-
1.58 (m, 4H), 1.53-1.41 (m, 2H), 1.40-1.13 (m, 6H), 1.13-1.10 (m, 1H), 1.07 (s, 3 H), 0.71 (s, 3 
H). Mass Spec m/z C19H30O3 Exact Mass 306.2195; Observed 306.2195. 
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(7aS)-5-[(1R,4S)-4-Hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl]-7a-methylperhydro-
1H-indene-4-carboxamide (3.52) 
A solution of ammonia in THF (9.12 mL, 0.5 M) was cooled to -78˚C. n-BuLi (1.7 mL, 2.5 M) 
was added dropwise and allowed to stir for 30 min. Lactone 3.51 (0.350 g, 1.14 mmol) was 
dissolved in a solution of 5.0 mL THF and added dropwise into the reaction before allowing the 
reaction to warm to rt The reaction continued for 24 hours. The reaction was diluted with NH4+Cl- 
(20 mL) and extracted successively with EtOAc (2 x 25 mL) The collected organic was washed 
with saturated NaCl (25 mL). The organic layer was dried with anhydrous MgSO4 and solvent 
removed under reduced pressure. This was subjected to column chromatography using (90% 
EtoAc/10% MeOH) to yield amide 3.52 as a white solid (0.195 g, 53%). TLC Rf  = 0.45 (90% 
ethyl acetate /10% methanol);  IR (neat) 3333, 3196, 1651 cm-1; 1H NMR (300 MHz, CD3OD) δ 
5.29 (d, J = 40.7 Hz, 2H), 3.87-3.73 (m, 1H), 3.66-3.51 (m, 1H), 3.29 (t, J = 9.25 Hz, 1H), 2.18-
2.05 (m, 2H), 2.04-1.95 (m, 1H), 1.89-1.74 (m, 3H), 1.73-1.56 (m, 6H), 1.50-1.37 (m, 6H), 1.36-
1.30 (m, 2H), 1.23-1.13 (m, 2H), 0.96 (s, 3H), 0.69 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 180.9, 
69.9, 61.1, 51.2, 44.7, 44.6, 42.4, 39.8, 39.4, 38.1, 37.4, 33.5, 30.4, 29.9, 26.1, 21.0, 19.6, 18.3, 
15.8. Mass Spec m/z C19H33NO3 Exact Mass 323.2460; Observed 323.2456. 
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(1S,4R)-4-[(7aS)-4-(aminomethyl)-7a-methylperhydro-1H-inden-5-yl]-3-(hydroxymethyl)-
4-methylcyclohexanol (3.53) 
 Amide 3.52 (0.100 g, 0.31 mmol) was dissolved in 3.0 mL of dry THF and cooled to 0˚C. LAH        
(4.64 mL, 1.0 M in THF) was added dropwise to the stirring solution. The temperature was 
increased to reflux for 20 h. The reaction was cooled to rt and diluted with THF before being 
cooled to 0˚C. Fieser method was used to work up the reaction. The filtered product was dried with 
MgSO4 and concentrated down to give the crude amine. Purification through column 
chromatography (9% methanol: 90% EtOAc: 1% NH4+OH-) yield amine 3.53 as a clear oil (0.033 
g, 34%). 1H NMR (300 MHz, MeOD) δ 3.75 (dd, J = 10.8, 1.8 Hz, 1H), 3.47 (septet, J = 15.2, 
10.9, 4.4 Hz, 1H), 3.22-3.08 (m, 2H), 2.75 (d, J = 14.4 Hz, 1H), 2.17 (d, J = 12.4 Hz, 1H), 1.86-
1.67 (m, 8H), 1.60-1.54 (m, 3H), 1.51-1.42 (m, 3H), 1.37-1.30 (m, 3H), 1.28-1.18 (m, 3H), 1.11 
(s, 3H), 0.79 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 697, 61.4, 49.7, 44.0, 43.4, 41.8, 40.2, 40.0, 
38.8, 38.7, 36.6, 33.8, 30.7, 25.6, 22.9, 20.0, 19.8, 16.2, 16.1. 
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(1S,4R)-4-[(7aS)-4-(Aminomethyl)-7a-methylperhydro-1H-inden-5-yl]-3-(hydroxymethyl)-
4-methylcyclohexanol ammonium chloride (3.43) 
Amine 3.53 (0.022 g, 0.071mmol) was dissolved in 3.0 mL Et2O. The reaction was stirred at rt 
while HCl (g) was bubbled into the solution. The solution was concentrated and the residue was 
washed with diethyl ether (2x) to yield the amine salt 3.43 as a white solid (0.019 g, 77%). 1H 
NMR (300 MHz, MeOD) δ 3.71 (dd, J = 11.0, 2.5 Hz, 1H), 3.45-3.35 (m, 1H), 3.21-3.00 (m, 2H), 
2.15 (d, J = 12.3 Hz, 1H), 1.91-1.67 (m, 8H), 1.63-1.38 (m, 6H), 1.36-1.18 (m, 6H), 1.07 (s, 3H), 
0.78 (s, 3H).   13C NMR (75 MHz, MeOD): δ 70.8, 62.6, 51.0, 45.6, 46.6, 43.0, 41.6, 41.2, 39.6, 
38.1, 37.4, 35.0, 31.9, 26.8, 24.0, 21.9, 21.1, 17.3, 15.4. Mass Spec m/z C19H35NO2 Exact Mass 
309.2668; Observed 309.2671. 
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5-androsta-7-one-3β,6-diol 17-ethylene ketal 3,6-di-tert-butyldimethylsilyl ether (3.29) 
 
A solution of tert-butyldimethylsilyl enol ether 3.27 (0.100 g, 0.17 mmol) in 3.0 mL DCM was 
cooled to 0˚C. NaHCO3 (0.122g, 1.45 mmol) was added and the reaction stirred 10 min before the 
addition of m-CPBA (0.45g, 0.260 mmol) in 3.0 mL DCM dropwise. After stirring for 30 min, aq. 
Na2S2O4 was added and the organic layer was collected. Organic was extracted with NaHCO3 (1x 
25 mL) and brine (1x 25 mL), dried with Na2SO4 and concentrated under reduced pressure. 3.29 
(0.059 g, 57%). 1H NMR (400 MHz, CDCl3) δ 3.94-3.74 (m, 5H), 3.47 (septet, J = 15.3, 10.3, 4.6 
Hz, 1H), 2.30-2.18 (m, 2H), 2.17-2.07 (m, 1H), 1.98-1.84 (m, 2H), 1.83-1.75 (m, 1H), 1.72-1.64 
(m, 3H), 1.52-1.22 (m, 7H), 1.13-1.02 (m, 5H), 0.86 (s, 9H), 0.83 (S, 9H), 0.79 (s, 3H), 0.07- -0.08 
(m, 12H). 13C NMR (100 MHz, CDCl3): δ 209.3, 118.7, 71.7, 65.2, 64.5, 55.0, 53.4, 48.2, 45.5, 
42.9, 36.9, 36.4, 34.1, 33.9, 31.4, 29.7, 25.9, 25.8, 23.5, 21.3, 18.7, 18.3, 14.4, 13.3, -4.42. 
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5-androsta-7,17-dione-3β,6-diol (3.30) 
 
3.29 (0.059 g, 0.10 mmol) was dissolved in 2.0 mL dioxane and 2.0 mL MeOH and 10% aq. HCl 
was added dropwise. Reaction stirred for 2 h before EtOAc was added. Organic was washed with 
aq. NaCl (1 x 10 mL) and dried over Na2SO4. Concentration under reduced pressure (0.023 g, 
72%).  1H NMR (400 MHz, CDCl3) δ 3.96 (d, J = 11.7 Hz, 1H), 3.68-3.41 (m, 2H), 2.69-2.55 (m, 
2H), 2.47 (dd, J = 19.4, 8.8 Hz, 1H), 2.32-2.08 (m, 2H), 2.03-1.70 (m, 6H), 1.63-1.40 (m, 4H), 
1.33-1.21 (m, 2H), 1.16 (s, 3H), 1.13-0.97 (m, 1H), 0.88 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 
211.0, 75.2, 70.5, 55.7, 54.3, 47.3, 47.0, 44.3, 36.5, 36.3, 36.2, 35.5, 33.4, 30.7, 30.6, 22..5, 21.2, 
13.8, 13.1. 
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Doctor of Philosophy: Chemistry                                      Syracuse University, Syracuse, NY 13244 
 GPA: 3.81                                                                                     August 2014 – August 2019  
 Major field of study: Synthetic Organic and Medicinal Chemistry 
 Advisor: John Chisholm, Ph.D.                                                               Defended: July 2019 
 
Master of Philosophy: Chemistry                                      Syracuse University, Syracuse, NY 13244 
 GPA: 3.81                                                                                                  August 2014 - 2016  
 Advisor: John Chisholm, Ph.D. 
 
Bachelor of Science: Chemistry                              Florida State University, Tallahassee, FL, 32306 
 GPA: 3.43                                                                                              Graduated: May 2014 
 
TEACHING EXPERIENCE 
 
Graduate Teaching Assistant – Organic Chemistry I and II 
                                                                       Syracuse University, January 2018 – December 2018 
Graduate Teaching Assistant – Organic Chemistry I and II 
                                                                       Syracuse University, January 2016 – December 2016 
Lead Graduate Teaching Assistant – Organic Chemistry I Lab 
                                                                         Syracuse University, August 2015 – December 2015 
Graduate Teaching Assistant – Organic Chemistry I and II Lab 
                                                                                  Syracuse University, August 2014 – May 2015 
Undergraduate Teaching Assistant – General Chemistry I Lab 
                                                                           Florida State University, January 2014 – May 2014 
 
RESEARCH EXPERIENCE 
 
Doctoral Research                                                  
                                                                                  Syracuse University, May 2015 – August 2019 
• Organic Synthesis and Medicinal Chemistry 
• Synthetic and Structure Activity Relationship Studies of SHIP inhibitors and agonists 
• Development of a shorter route to the patented SHIP 1 agonist AQX-1125 
• Development and synthesis of the more potent SHIP 1 agonist K204 
• Characterization of small organic compounds by NMR, IR, mass spectroscopy, and 
combustion analysis 
 
PRESENTATIONS 
 
1. “Synthetic studies on the seco-steroidal indene AQX-1125” (O. M. Dungan, B. C. Duffy, D. 
G. Effiong, W. G. Kerr, J. D. Chisholm) presented by O. Dungan at the Poster Session for the 
256th ACS National Meeting, Boston, Massachusetts, 2018. 
 222 
 
2. “Synthetic Studies on AQX-1125” (O. M. Dungan, D. G. Effiong, W. G. Kerr, J. D. Chisholm) 
presented by O. Dungan at the Poster Session for Visiting Students, Department of Chemistry, 
Syracuse University, Syracuse, New York, March, 2018. 
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4. “Tethered Systems for Homogenoeous and Heterogeneous 2:1 Charge-Transfer Complexes,” 
(J. M. Watts, O. Dungan, E. J. Lavelle, Y. W. Kahok, R. T. Kearney, B. C. Bowden, and E. F. 
Hilinski) presented by O. Dungan at the Poster Session for Visiting Students, Department of 
Chemistry and Biochemistry, Florida State University, Tallahassee, Florida, February, 2014. 
 
5. “Tethered Systems for Unsymmetrical 2:1 Electron Donor-Acceptor Complexes,” (J. M. 
Watts, E. D. Webb, J. B. Mullenix, N. B. Kerckhoff, J. P. Gershenson, O. Dungan, and E. F. 
Hilinski) presented by O. Dungan at the Poster Session for Visiting Students, Department of 
Chemistry and Biochemistry, Florida State University, Tallahassee, Florida, February, 2013. 
 
6. “Tethered Systems for Homogenoeous and Heterogeneous 2:1 Charge-Transfer Complexes,” 
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3. Dungan, O.; Fernandes, S.; Duffy, B. C.; Kerr, W. G.; Chisholm, J. D. "Discovery of a new 
class of SHIP1 Agonists." In preparation. 
